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RÉSUMÉ 
 
Le diabète sucré est déclenché par une perte de fonction et/ou du nombre total de cellules 
productrices d’insuline, les cellules β, que l’on trouve au sein des « Îlots de Langerhans » du 
pancréas. La greffe d’îlots est une des voies de traitement du diabète actuellement étudiée, et les 
avancées dans le domaine de l’ingénierie tissulaire pourraient améliorer la survie et la 
fonctionnalité des îlots transplantés. Lors de leur purification et de leur transplantation, les îlots 
subissent de nombreuses agressions : stress physiques et chimiques, la réponse immunitaire du 
patient greffé, infections post-opératoires, etc. Il est donc nécessaire de comprendre et d’améliorer 
les procédés de transplantation mais aussi de vérifier la fonctionnalité des îlots avant leur 
transplantation. Cette thèse a pour objectif de comprendre in vitro la fonctionnalité et la survie des 
îlots isolés en étudiant leur comportement dans un environnement 2D et dans un environnement 
3D constitué de leur matrice extracellulaire native (MEC). Des pancréas de souris ont été 
décellularisés puis les îlots isolés ont été injectés dans le pancréas décellularisé. La viabilité et la 
fonctionnalité des îlots dans ce système ont été évaluées après 48h par coloration et par analyse de 
la sécrétion d’insuline par stimulation au glucose (GSIS). Ce manuscrit présente l’ensemble de la 
procédure de décellularisation du pancréas ainsi qu’une nouvelle technique d’injection d’îlots. La 
seconde partie de la thèse présente la solubilisation du pancréas décellularisé et l’immobilisation 
de ces extraits solubilisés sur des surfaces pour cultiver des îlots. Trois méthodes détaillées de 
solubilisation sont présentées (digestion à la pepsine, solubilisation par l’acide acétique et 
solubilisation par le NaOH). Des îlots isolés ont été cultivés sur ces surfaces biomimétiques et leur 
viabilité et fonctionnalité ont été évaluées. La dernière partie expérimentale de la thèse présente 
une comparaison du profil de sécrétion de l’insuline entre des îlots individuels et des populations 
d’îlots. Le profil cinétique a été modélisé à partir d’îlots cultivés seuls ou en groupe pendant 72h, 
et ce, in vitro. Trois profils cinétiques de sécrétion de l’insuline ont été observés (lent, rapide, et à 
taux constant), et nous avons analysé l’influence de la taille des îlots sur le profil cinétique de 
sécrétion. Les résultats observés lors des mesures traditionnelles de sécrétion d’insuline par 
stimulation au glucose (GSIS) sont discutés au regard des trois profils cinétiques de sécrétion. 
Mots clés : Matrice extracellulaire, pancréas, îlots de Langerhans, cinétique de sécrétion 
d’insuline, transplantation d’îlots, pancréas décellularisé, extraction de protéines de la MEC.  
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ABSTRACT 
Diabetes Mellitus involves the loss of function and/or absolute numbers of the insulin-producing 
β-cells normally located within the “Islets of Langerhans” of the pancreas. Islet transplantation is 
currently being investigated as a potential cure, and advances in tissue engineering is hypothesized 
to improve pancreatic islets survival and functionality. During isolation and transplantation, islets 
undergo physical damage, chemical damage, host-immune rejection, post-op infection, technical 
failures and graft failures. Therefore, it is essential to understand and improve the process of 
transplantation and, also, it is important to know the functionality of isolated islets before 
transplantation. This thesis aims to address these issues by understanding the functionality and 
survival of isolated pancreatic islets in vitro, by studying their behavior when cultured in 2D and 
3D environments made of their native extracellular matrix (ECM). Also, insulin release kinetics 
of isolated single pancreatic islets was investigated and compared to those of pools of islets. The 
first experimental work includes the decellularization of mouse pancreata and infusing the freshly 
isolated islets into the decellularized pancreata. Glucose-stimulated insulin secretion (GSIS) and 
viability assays were performed on these islets to show the functionality and health of the islets 
after 48h of culture into the decelluarized pancreata. This section describes the full procedure of 
pancreas decellularization with a novel method to infuse islets into pancreata. The second 
experimental work describes the solubilisation of decellularized pancreata and the surface-
immobilization of the extracts to culture islets. This study presents the detailed protocol of 
extraction of decellularized pancreata by three methods (pepsin digestion as well as acetic acid 
and NaOH solubilisation). The freshly isolated islets were cultured on these resulting biomimetic 
surfaces and the results of functionality and viability of these islets were discussed. The third 
experimental work focuses on the comparison of insulin kinetics between single islets and pools 
of islets. Freshly isolated individual islets and pools of islets were cultured in vitro for 72h and the 
kinetics of insulin release were modeled. Three modes of insulin secretion kinetics were revealed 
(slow-, fast- and constant-rate secretors), along with discussion on the effect of islet size on insulin 
release. In addition, the results of traditional GSIS on islets were compared with these secretion 
profiles. 
Keywords: ECM, diabetes, pancreas, islets, insulin secretion kinetics, islet transplantation, 
decellularized pancreas, ECM protein extraction. 
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Chapter 1 
 
INTRODUCTION 
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In 2015, the International Diabetes Federation estimated that 415 million people worldwide have 
been diagnosed with diabetes; with an estimated increase to 642 million by 2040. In 2017, the 
Canadian Diabetes Association reported that there are 11 million Canadians living with diabetes 
or prediabetes, the treatment of which still remains a huge physiological or medicinal, and 
socioeconomic problem. 
In 1979, the terms type-I (T1DM) and type-II (T2DM) were assigned to classify the diabetic 
phenotypes; earlier it was called insulin dependent diabetes mellitus or juvenile diabetes, and non-
insulin dependent diabetes mellitus or adult-onset diabetes, respectively [1]. 
T1DM is caused by the autoimmune destruction of insulin-producing β cells of the pancreas [2]. 
There are several factors including viral, bacterial, environmental, life style, and genetics which 
have all been associated with the pathophysiology of T1DM [3]. Due to the destruction of these 
cells, they can no longer produce insulin in response to glucose, thus, creating reliability on an 
exogenous supply of this hormone indispensable to normalize the blood glucose levels. This 
process is essential for long-term survival. A possible cure for T1DM came in 1966 when the first 
transplantation of a whole pancreas was successfully performed. Alike to other major organ 
transplantations, whole pancreas transplantation continues to have morbid risks including surgical 
complications, post-op infection, technical failures, donor obesity which all influence the success 
and long-term survival of such a graft [4]. Furthermore, the recipient also requires lifelong 
immunosuppressant drugs. Given this, transplanting islets of Langerhans may offer a less invasive, 
lower risk, alternative cure for T1DM. Recipients of islet transplantation attained insulin 
independence with normoglyceamia for a stipulated period of time, post-transplantation. This 
result combined with the less invasive nature of this transplantation reduced the overall post-
surgical complications and improved the clinical outcome of the patient using less 
immunosuppressant drugs [5, 6]. 
The major limiting factors for islet transplantation include limitation of donors for the source of 
islets, immune rejection, damages of islets and of the extracellular matrix (ECM) during isolation 
as well as poor revascularization post transplantation [7]. 
Islets encapsulation could provide a possible solution to protect isolated islets. Three major 
advantages of islet encapsulation are: 1. to protect islets from host-immune rejection, 2. to re-
establish the lost ECM to avoid anoikis and cell death and 3. to allow diffusion of molecules. 
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This thesis mainly focuses on the improvement of islet culture methods by providing information 
on islets behaviour in vitro on 2D and 3D ECM and the kinetics of insulin release revealing the 
full potential of isolated islets in terms of insulin secretion towards glucose stimulation. 
 
Chapter 2 titled ‘Tissue and Organ Decellularization in Regenerative Medicine’ is a review of the 
scientific literature. Major tissues/organs used for decellularization including the recent techniques 
and chemicals involved in decellularization and their outcomes are discussed. This review also 
highlights the inevitability of ECM molecules and the possible immune reactions faced by these 
ECM scaffolds when transplanted. In addition, applications, status and perspective of 
decellularized tissues and organs are discussed in detail. 
 
Chapter 3 consists of an experimental paper titled ‘Decellularized Pancreas as a Native 
Extracellular Matrix Scaffold for Islets’. Mouse pancreata were decellularized and then isolated 
islets were perfused into the decellularized organ, thus, concluding that these islets were viable 
and functional after 48h in vitro. 
 
Chapter 4 is an experimental paper titled ‘Solubilisation of Decellularized Pancreata and 
Immobilization on Low-Fouling Surfaces for Islet Culture’. Briefly, the decellularized pancreata 
were solubilised using three different methods (pepsin, acetic acid and NaOH treatments). The 
extracted proteins were immobilized on low-fouling surfaces to culture freshly isolated pancreatic 
islets for 5 days. The results revealed that the islets were viable and functional after 5 days on the 
biomimetic surfaces. 
 
Chapter 5 consists of an experimental paper titled ‘Insulin Secretion Kinetics from Single Islets 
Reveals Distinct Sub-Populations’. 58 islets were freshly isolated from mouse pancreata and 
cultured on tissue culture polystyrene (TCPS) for 72h at four glucose concentrations. The results 
revealed that the islets responded to glucose by three different insulin secretion profiles (slow, fast 
and constant rate secretors), and most of the islets were characterized as slow secretors. 
 
Chapter 6 presents a conclusion and future perspectives of the study. 
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Chapter 2 
 
Tissue and Organ Decellularization 
in Regenerative Medicine 
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Résumé 
 
L’augmentation de la demande en tissus et organes à transplanter a entrainé l’essor de la recherche 
sur la décellularisation tissulaire. La préparation d’organes et de tissus décellularisés implique 
l’élimination de leur contenu cellulaire et génomique tout en conservant la structure complexe de 
la matrice extracellulaire (MEC) pour jouer le rôle de support possédant une fonction 
physiologique. De nombreux tissus et organes ont été décellularisés avec succès et utilisés en 
recherche ou comme produits commerciaux. Différentes techniques sont utilisées : traitements 
mécaniques, chimiques ou biologiques, qui possèdent toutes leurs avantages et inconvénients. Cet 
article de revue présente les récents développements dans les méthodes de décellularisation, 
l’importance de la nature des détergents utilisés, ainsi que le rôle de la MEC soit comme support 
physique, soit comme support et source des signaux pour la survie cellulaire, la différenciation 
cellulaire et l’homéostasie. Nous présentons également les applications et les statuts actuels des 
bioproduits commercialisés à partir de tissus et d’organes décellularisés. 
 
Mots clés : décellularisation; recellularisation; ensemencement cellulaire; organes artificiels; 
détergents; matrice extracellulaire (MEC); cellules souches; commercialisation 
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Abstract 
 
The advancement and improvement in decellularization methods can be attributed to the increasing 
demand for tissues and organs for transplantation. Decellularized tissues and organs, which are 
free of cells and genetic materials while retaining the complex ultrastructure of the extracellular 
matrix (ECM), can serve as scaffolds to subsequently embed cells for transplantation. They have 
the potential to mimic the native physiology of the targeted anatomic site. ECM from different 
tissues and organs harvested from various sources have been applied. Many techniques are 
currently involved in the decellularization process, which come along with their own advantages 
and disadvantages. This review focuses on recent developments in decellularization methods, the 
importance and nature of detergents used for decellularization, as well as on the role of the ECM 
either as merely a physical support or as a scaffold in retaining and providing cues for cell survival, 
differentiation and homeostasis. In addition, application, status and perspectives on 
commercialization of bioproducts derived from decellularized tissues and organs are addressed. 
 
Keywords: Decellularization; Recellularization; Cell seeding; Artificial organs; Detergents; 
Extracellular matrix (ECM); Stem cells; Commercialization  
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2.1 Introduction 
 
Increased demand for tissues and organs for transplantation has expanded the fields of research on 
decellularization. Preparation of decellularized tissues and organs involves removal of cells and 
genetic materials from the tissue or organ and retention of the complex ultrastructure of the 
extracellular matrix (ECM) to serve as a natural scaffold. The ECM is produced by the native cells 
and serves as a mechanical support and cues for cell migration, attachment, differentiation and 
function [8, 9]. Many tissues and organs have been successfully decellularized and used for 
research and commercial purposes. Different techniques including physical, chemical and 
biological methods are currently applied in decellularization and these have their own pros and 
cons. 
The two important criteria to be fulfilled during a decellularization procedure are: 1. 
retention of the native structures and 2. removal of a maximum of cell components. Several tissues 
and organs such as the small intestine, bladder, placenta and liver, only to name a few, have been 
decellularized and used as ECM scaffolds [10-13]. Recent advances in regenerative medicine and 
tissue engineering have paved the path for investigating the use of whole decellularized organs for 
transplantation. Many in vitro and in vivo studies support that ECM-based scaffolds made of 
decellularized tissues and organs have beneficial effects on cells, including stem cells, in terms of 
their attachment, proliferation, viability and functionality. In favor to that, these scaffolds have a 
low immunogenicity, which facilitates their in vivo applications [13, 14]. 
Over the past 20 years, decellularized tissues and organs have been commercially available 
for wound healing. Companies are working to commercialize ECM-based products for organ 
transplantation, which some are in clinical trials. 
The objective of this review is to give an update on the most important tissues and organs 
that are used for decellularization, the importance of ECM as a complete set of biomolecules, the 
techniques and chemicals applied in decellularization operations, the rationale behind using ECM-
based bioproducts, as well as applications, perspectives and path to commercialization. 
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2.2 Major tissues and organs used for decellularization 
 
2.2.1 Liver 
 
The liver is one of the important organs, which has been decellularized for regenerative medicine. 
The first successful liver decellularization was done by surface treatment with detergents and the 
resulting bioproduct was recellularized with rat hepatocytes to assess functionality [15]. Surface 
treatment refers to decellularizing a tissue or an organ by immersion in decellularizing solutions 
as opposed to perfusion decellularization, which involves perfusing solutions within the tissue or 
organ. Studies on liver decellularization report the perfusion of detergents through the network of 
veins and arteries, then its recellularization and in vivo transplantation [16-18]. For example, 
seeding rat hepatocytes into decellularized liver and subsequent transplantation in rats showed that 
less damages occurred to the cells following an 8h transplantation, as revealed by TUNEL staining 
[16]. In a separate study, when human liver stem cells were seeded in decellularized rat liver, 
differentiation into functional hepatocytes was observed as well as the presence of epithelial and 
endothelial-like cells [19]. Research on achieving human-sized whole liver has also been attempted 
with pigs by decellularizing the organ with SDS (sodium dodecyl sulfate) [20, 21]. 
2.2.2 Heart 
 
Heart decellularization techniques started initially with heart valves by surface decellularization 
using detergents and subsequent recellularization with different cell types [22-24]. Introduced in 
2008, decellularization of whole hearts from rats was done by perfusion methods and the resulting 
scaffolds were seeded with cardiac and endothelial cells; contraction in cell patches was observed 
after 4 days [25]. Recent advances in heart decellularization aim to improve perfusion processes 
during decellularization and cell seeding with progenitors as well as to achieve decellularization 
of organs from larger animals [26-30]. Allo-transplanted porcine heart seeded with mesenchymal 
stem cells (MSCs) showed thrombosis in arteries as well as the presence of inflammatory cells and 
the observation was similar to decellularized heart transplanted without mesenchymal stem cells 
[31]. In addition, a 14-day culture of human cardiomyocytes in human decellularized heart showed 
visible contraction when electrically stimulated [32]. 
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2.2.3 Lungs 
 
Decellularized lungs were considered as a source of bioartificial organs for transplantation in end-
stage lung diseases. The first successful perfused decellularization was reported in 2010 following 
methods initially applied to heart and liver [33]. Recent works on decellularizing lung involve the 
improvement of decellularization process and cell seeding methods, as well as studies on the role 
of stem cells [33-35]. Attempts to decellularize human lungs are step closer to fill the gap in the 
demand for organ transplantation [36, 37]. Stabilization of endothelial cells by seeding adipose-
derived stem cells into decellularized lungs could be a potential solution to regenerate the 
vasculature of decellularized lungs [38]. Seeding mesenchymal stromal cells in decellularized lung 
in suspension bioreactor resulted in differentiation of the cells into collagen-1 alpha-1 producing 
cells [39]. In another study, human-induced pluripotent stem cells (iPSC)-derived endothelium and 
ventralized iPSC were seeded in decellularized lungs resulting in retention of epithelial progenitors 
phenotype by expressing Nkx21 and endothelial phenotype by expressing CD31 [40]. 
Transplantation of decellularized rat lung seeded with epithelial and endothelial cells maintained 
the animals alive without ventilation for 6h [33]. 
2.2.4 Pancreas 
 
The first perfused decellularization of pancreas was carried out in 2009 with a porcine organ [41] 
and then applied to mouse [42]. The decellularized tissues were used to seed cells and islets and 
their in vitro functions were studied as well as the biocompatibility of these bioartificial pancreata 
was investigated in vivo [41-44]. Later, rat pancreata were decellularized and a new method was 
introduced to infuse islets into the ducts, veins and arteries [45]. Decellularized pancreata were 
seeded with human stem cells, an AR427 acinal cell line, MIN-6 cells and islets, and cell 
attachment as well as basic cell functions were studied [42-45]. Recently published work from our 
group demonstrated that islets infused into the ductal system of decellularized pancreata were 
functional by releasing insulin in response to glucose stimulation after 48 days in vitro [46]. 
  
11 
 
 
2.2.5 Small intestinal submucosa (SIS) 
 
One of the first usages of SIS was during 1989, as a vascular graft for dogs [47]. SIS biomaterials 
are widely used in regenerative medicine, for example to reconstruct urethra, cornea, oesophageal, 
and heart [48-51]. Recently, SIS seeded with urothelial cells showed formation of new vessels, 
proliferation of smooth muscle cells, epithelization and maintenance of the opening of urethra 
when compared to unseeded scaffold [52]. Reconstruction of cornea was accomplished 
successfully in 106 cases by preserving vision at third month of post-surgery using porcine SIS 
[53]. Seeding autologous oral mucosa epithelial cells along with SIS resulted in muscular 
regeneration and re-epithelization after 8 weeks of surgery and the results were superior to SIS 
with no cells [54]. Applying FDA-approved SIS ECM seeded with mesenchymal stem cells 
resulted in a lower response of the adaptive immune system in a porcine model, when compared 
to SIS-ECM with no cells [55]. 
2.2.6 Bladder 
 
Urinary bladder has been one of the oldest organs selected for decellularization. Recent studies on 
ECM derived from decellularized bladder has indicated a beneficial effect on neuron survival, 
stem cells, spinal cord and open wounds [56-59]. Urinary bladder-derived ECM has shown greater 
advantage than cardiac-derived ECM in remodelling and for attracting site-specific cells 
(cardiomyocytes) after implantation [60]. The implantation of large segments (>24cm2) of urinary 
bladder into porcine bladder showed infiltration of smooth muscle cells and promoted 
angiogenesis after 30 days [61]. Vesicles derived from urinary bladder ECM had a positive effect 
on neuron neurite growth and on spinal cord injury repair [57, 58]. Urinary bladder-derived ECM 
also had a better effect on the treatment of open wounds when compared to conventional therapies 
[56]. Bioproducts made from urinary bladder-derived ECM are available in different formulations 
such as sheets (Cytal® Burn Matrix, also marketed as MatriStem® Burn Matrix, ACELL 
(Columbia, USA); the product is applied directly on wounds), powder (MicroMatrix®, ACELL 
(Columbia, USA)) and hydrogels (not available commercially). 
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2.2.7 Kidneys 
 
The initial method of decellularization of whole kidneys was achieved by perfusion techniques 
and the resulting products were used to seed and differentiate stem cells [41, 62]. Advances in 
kidney decellularization include in vitro and in vivo studies on rat and mouse kidneys to investigate 
the functionality of recellularized kidneys with endothelial, epithelial and renal progenitor cells 
[63, 64]. 
2.2.8 Bones and cartilage  
The successful removal of cells from bones and cartilages was achieved in 2011[65]. Recent 
advancements in cartilage and bone repair include utilizing adipose-derived stem cells, multipotent 
stromal cells seeded on decelluarized cartilage ECM to study the mechanical properties and bone 
regenerative capacity [66, 67]. 
2.2.9 Plants 
 
Recent advancements in tissue and organ decellularization have extended their boundaries to apply 
perfused decellularization protocols on plant leaves and eventually recellularize them with 
cardiomyocytes resulting in contractile function successfully for 21 days [68]. 
2.3 Recent decellularization methods 
 
Over the years, several studies have been conducted to understand the utility of decellularized 
tissues and organs in regenerative medicine. Table 1 below provides a summary of recent studies 
highlighting the various techniques and their corresponding results on decellularized tissues and 
organs. 
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Table 1: Recent studies involving decellularization methods and their outcomes. 
 
Organ 
or tissue 
Species Applications Methods Chemicals Results References 
Liver 
Mouse 
Culture of mouse 
hepatocytes 
Non-thermal 
irreversible 
electroporation 
- 
Cell integration into the 
host liver parenchyma 
[69] 
Rat 
Hepatocyte seeding 
and transplantation 
into rat 
Perfusion 
through portal 
vein 
SDS (0.01, 0.1 and 
1%) 
Preservation of functional 
and structural 
characteristics of 
microvascular network and 
display of liver-specific 
functions 
[16] 
Decellularization 
using increasing 
detergent 
concentration 
Perfusion 
through portal 
vein 
1, 2 and 3% Triton X-
100 
+ 0.1% SDS 
Retention of laminin in the 
basement membrane 
and collagen IV 
[70] 
Minimizing ECM 
damage 
Arterial 
perfusion 
under 
oscillation 
1% Triton X-100 
+ 1% SDS 
Fast, homogenous, higher 
concentration of 
hepatocyte growth factor 
compared to the native 
[71] 
14 
 
Organ 
or tissue 
Species Applications Methods Chemicals Results References 
pressure 
conditions 
tissue, high GAG 
concentration and gentle 
method of decellularization 
Pig 
Comparison of three 
detergent mixtures 
for decellularization 
and recellularization 
with rat hepatocytes 
Perfusion de-
cellularization 
and freeze-
thaw 
1% SDS; 
1% Triton X-100 + 
1% sodium 
deoxycholate; 
1% sodium 
deoxycholate + 1% 
SDS 
Cell removal, preservation 
of ECM structure 
and biocompatibility, 
achieved by 
1% Triton X-100 + 1% 
sodium deoxycholate 
[18] 
Kidneys Pig 
Study on 
decellularization 
methods 
Perfusion 
using a high-
throughput de-
cellularization 
apparatus 
water and 0.5% SDS 
Preservation of important 
ECM components, intact 
vasculature tree, in vitro 
biocompatibility for cells 
and preservation of gross 
anatomy after 
2 weeks of implantation 
[72] 
Heart Rat 
Recellularization 
with aortic 
endothelial cells and 
Coronary 
perfusion 
1% SDS 
Performance of basic 
functions 
[73] 
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Organ 
or tissue 
Species Applications Methods Chemicals Results References 
rat neonatal 
cardiomyocytes 
Zebra 
fish + 
Mouse 
In vitro proliferation 
and migration of 
human cardiac 
precursor cells 
Freeze-thaw 
cycles 
 
Exhibition of pro-
proliferative and 
chemotactic effect with 
human cardiac precursor 
cells by Zebra fish ECM 
including structural 
preservation and cardiac 
contractile function 
[74] 
Pig 
Comparison of two 
detergents 
Surface 
treatment 
1% Triton X-100 + 
nucleases + trypsin 
and sodium 
deoxycholate with and 
without nucleases 
 
Complete cell removal and 
preservation of ECM 
structures by Triton X-100 
+ nucleases + trypsin 
[75] 
Myocard
-ium 
Pig 
Comparison of 
decellularizing 
agents and 
recellularization with 
Surface 
treatment 
1% SDS; 
1% Triton X-100; 
0.5% trypsin 
Effective decellularization 
by SDS and 
retention of ECM 
microstructures. 
[76] 
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Organ 
or tissue 
Species Applications Methods Chemicals Results References 
rat myocardial 
fibroblasts 
Display of different beating 
magnitudes of seeded cells: 
largest beating magnitude 
in trypsin, moderate in SDS 
and 
none in Triton X-100-
treated scaffolds 
Teeth Human 
Comparison of 
decellularization 
methods 
Surface 
treatment 
10% formaldehyde, 
PBS + EDTA + 2.5% 
sodium hypochlorite; 
PBS + EDTA + 
40v (40 volume or 
12%) hydrogen 
peroxide; 
PBS + 2.5% sodium 
hypochlorite 
+ Ryozime®; 
PBS + EDTA + 
40 v hydrogen 
peroxide + Ryozime® 
Maximal removal of 
biological particles and less 
damage to the structures 
obtained with PBS + 
EDTA + 40 v hydrogen 
peroxide + Ryozime® 
[77] 
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Organ 
or tissue 
Species Applications Methods Chemicals Results References 
Bones 
and 
cartilages 
Rat 
Calvaria 
regeneration in vivo 
and recellularization 
with mesenchymal 
stem cells 
Surface 
treatment 
0.5% SDS + 
0.1% ammonium 
hydroxide 
Formation of new bone and 
merging with the host bone 
after 3 months. 
Proliferation and 
osteogenic differentiation 
of mesenchymal stem cells 
[78] 
Pig 
Tissue 
characterization and 
recellularization with 
murine fibroblasts 
and porcine 
chondrocytes 
Surface 
treatment 
1% SDS 
Retention of compatible 
tension properties of intact 
tissue but reduction in 
compression. 
No cytotoxicity on 
recellularized cells 
[79] 
Bovine 
Tissue 
characterization and 
recellularization with 
human adipose 
mesenchymal stem 
cells 
Surface 
treatment 
10 mM 
Ethylenediaminetetra-
acetic acid disodium 
salt dihydrate 
(Na2EDTA, pH 7.2–
7.4) 
Chondrogenic 
differentiation of human 
adipose mesenchymal stem 
cells 
[80] 
Skeletal 
Muscle 
Pig 
Comparison of 
decellularization 
Surface 
treatment 
1% SDS; 1% SDS 
Formation of jelly-like 
hydrogel by using 
[81] 
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Organ 
or tissue 
Species Applications Methods Chemicals Results References 
methods and 
formulation of 
hydrogel scaffolds 
+ 0.2% sodium 
deoxycholate; 
1% SDS + 1% Triton 
X-100; 
1. 0.2% Trypsin/0.1% 
EDTA, 2. 0.5% Triton 
X-100, 3. 1% Triton 
X-100/0.2% sodium 
deoxycholate 
0.2% trypsin/0.1% EDTA, 
0.5% Triton X-100, 
and 1% Triton X-100/0.2% 
sodium deoxycholate 
treatment 
Nerve Rat 
Reconstruction of 
long gap nerve injury 
Surface 
treatment 
(Dulbecco’s modified 
Eagle medium + 10% 
fetal bovine serum and 
4% 
penicillin/streptomyci
n/amphotericin B) + 
(DMEM with 10% 
fetal bovine serum and 
2% 
penicillin/streptomyci
n/ 
amphotericin) + PBS 
Exhibition of functional 
nerve regeneration in vivo 
[82] 
Skin Mouse 
Comparison of 
detergent-free 
decellularization 
Surface 
treatment 
(50nM latrunculin B + 
Dulbecco’s modified 
Eagle medium) +  0.6 
Retention of matrix 
composition and 
biomechanical property 
[83] 
19 
 
Organ 
or tissue 
Species Applications Methods Chemicals Results References 
with ionic and 
anionic detergents 
for decellularization 
mol/L potassium 
chloride + 1.0 M 
potassium iodide 
with detergent-free 
decellularization method, 
but, bio-functionally all 
methods responded equally 
Trachea Rabbit 
In vivo 
transplantation 
Freeze-drying, 
detergent and 
sonication 
1% SDS 
Exhibition of necrosis and 
animal death in 7-24 days 
and integration of 
decellularized scaffold into 
the host structure was 
observed 
[84] 
Spleen Rat 
Recellularization of 
bone marrow 
mesenchymal stem 
cells (BMSCs) 
Freeze-thaw 
cycles and 
perfusion 
decellularizatio
n 
0.1% trypsin, 0.05% 
EDTA, 3% Triton X-
100 
Differentiation of BMSCs 
into functional hepatocyte-
like cells 
[85] 
Culture of rat 
hepatocytes 
Perfusion 
decellularizat-
ion 
0.1% SDS 
Survival and secretion of 
urea and albumin for 10 
days in culture 
[86] 
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Organ 
or tissue 
Species Applications Methods Chemicals Results References 
Pancreas 
Mouse 
Recellularization of 
MIN-6 cells and 
AR42J 
Perfusion 
decellularizat-
ion 
0.5% SDS 
Upregulation of insulin 
gene in vitro, less immune 
reaction and angiogenesis 
after 14 days in vivo 
[42] 
Recellularization of 
MIN-6 cells and in 
vivo implantation 
Freeze-thaw at 
-800C for one 
day followed 
by perfusion 
decellularizat-
ion 
1% Triton X-100 + 
0.1% ammonium 
hydroxide 
Biocompatibility and 
angiogenesis induction 
[44] 
Rat 
Comparison of three 
perfusion routes for 
decellularization and 
recellularization of 
islets 
Perfusion 
decellularizat-
ion 
1% Triton X-100 
+ 0.5% SDS 
Reach of islets into 
parenchymal space of the 
pancreas after infusion 
through ductal system 
[45] 
 
BMSCs: bone marrow mesenchymal stem cells; ECM: extracellular matrix; GAG: glycosaminoglycans; 
PBS: phosphate-buffered saline; SDS: sodium dodecyl sulfate
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2.4 Chemicals used for decellularization 
 
Any decellularizing procedure involves disruption of the ECM. The selection of decellularizing 
agents causing the least possible damage to the ECM is vital. The choice of decellularizing agents 
depends on the nature of the tissue or organ. A decellularization operation involves notable 
changes in the tissue and organ color, starting from its original color to become translucent. The 
process consists in removing cellular components and nuclear materials. Destruction of the cell 
membrane, dissolution of cellular components and removal of nucleic acid materials are the key 
steps. 
Alkalis and acids dissolve cellular components and wash nucleic acids [87]. Detergents 
solubilize cell membranes and remove cellular components and nucleic acids [88]. 
Detergents are soluble amphiphiles, which can solubilize biological membranes. They have 
both hydrophilic and hydrophobic groups with a more hydrophilic nature than biological 
membranes. They can be classified according to their charges: non-ionic, anionic, cationic and 
zwitterionic detergents [89, 90]. Triton X-100, a non-ionic detergent, is commonly used for cell 
lysis and permeabilization [91, 92]. The hydrogen bonds in lipid bilayers are disrupted by the polar 
head group of Triton X-100, breaking the cell plasma membrane [89]. In some studies, Triton X-
100 has been reported to be the best decellularizing agent compared to other detergents and that 
for many tissues and organs including ligaments, small intestine, annulus fibrosus, liver and aortic 
valves [49, 93-96]. On the other hand, some studies demonstrated that Triton X-100 had poor cell 
removal capacity for many tissues and organs such as veins, cornea, urethra, heart and kidneys 
[25, 97-100]. 
Another detergent commonly used in decellularization protocols is sodium dodecyl sulfate 
(SDS). SDS is an anionic detergent, used mainly in commercial applications such as in cleaning 
and in the making of cosmetics. SDS is also well known in biochemistry for its use in the SDS-
PAGE technique. Its application in decellularization can be counterintuitive when aiming to 
preserve the tissue or organ ECM structure intact, as SDS is known to denature proteins [101]. 
SDS solubilizes membrane proteins and thus helps effectively in the decellularization process. 
SDS incorporates into the outer membrane layer by increasing its curvature, creating a stress which 
results in membrane disruption [102]. SDS proved to be superior when compared to other 
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detergents in removing cells and genetic materials in many tissues and organs including aorta, 
veins, heart, kidneys and urethra [25, 97, 99, 100, 103]. Triton X-100 and SDS have also shown 
negative influence on tissues and organs used for decellularization but, on the other hand, when 
these two detergents were used in combination, the mixture allowed efficient decellularization and 
preservation of ECM structures and this has been tested on tendons, kidneys, small intestinal 
submucosa and liver [18, 50, 104, 105]. 
Another ionic detergent/bile salt frequently used in decellularization is sodium 
deoxycholate (SDC). After adhering to the membrane, SDC incorporates its cholate moiety into 
the lipid membrane, resulting in pore formation and membrane disruption [106]. SDC, alone or in 
combination with other detergents, has shown to be effective in removing cells while retaining 
ECM structures in decellularized tissues [23, 107]. 
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate, is 
another detergent used in decellularization. CHAPS is a zwitterionic detergent with a hydrophilic 
side and a hydrophobic back. CHAPS does not result in pore formation; instead, the molecules 
seem to directly break the lipid membrane [108]. CHAPS has proven to be milder and to have 
greater ability to retain mechanical strength in lungs [34, 37, 109]. 
Other chemicals applied in decellularization protocols are acids and bases. Both acids and 
bases had a negative impact on the ECM mechanical strength [110]. Acetic acid-treated bovine 
pericardia had reduced tensile strength but, on the other hand, it supported the growth of human 
mesenchymal stem cells and, hence, proved to be biocompatible [111]. Peracetic acid along with 
ethanol was used to sterilize decellularized scaffold materials, a well-known and FDA-approved 
method for medical devices [13]. However, the use of peracetic acid for decellularization resulted 
in incomplete cell removal from tumor ECM, porcine liver and kidneys [112, 113]. 
Decellularization of skin using NaOH had a cytotoxic effect on fibroblasts, however, prolonged 
washing of the scaffold helped in decreasing this cytotoxic effect [114]. Alcohols or acetone 
solutions can be used in the pre-treatment of tissues for lipid removal. It is easier to lyse and 
remove cells after eliminating lipid contents [115]. Acetone/alcohol combinations had a negative 
effect on tissue dehydration and greater influence on modifying mechanical properties and 
morphology of temporomandibular joint from pig jaws, as compared to SDS-treated tissues [116]. 
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Along with chemicals, the use of enzymes in decellularizing techniques can be 
advantageous. It is not possible to decellularize tissues or organs only with enzymes. However, 
enzymes are involved in the removal of cell debris. The most commonly used enzymes are trypsin, 
nucleases, collagenase, thermolysin, α-galactosidase and dispase [110, 117]. 
2.5 Rationale for using extracellular matrix (ECM)-based products 
 
ECM proteins have shown positive influence on cell growth, function and differentiation and 
examples of biomimetic surfaces have been reviewed by us [118]. 
An important class of ECM-derived proteins is that of collagens, as reviewed elsewhere 
[119]. Collagen is in fact an abundant source of ECM proteins. For example, collagen 
microspheres can differentiate oligodendrocyte progenitors into oligodendrocytes and collagen-
immobilized nanowires had a positive influence on human microvascular endothelial cells [120, 
121]. Fibronectin and laminin showed numerous positive effects on cell survival and functions 
both in vitro and in vivo [122, 123]. In the past years, our group has verified the positive effects of 
various ECM peptides and proteins. For example, immobilization of fibronectin, fibrinogen and 
fibrin on polymer surfaces enhanced the proliferation of smooth muscle cells [124]. Also, 
embedding pancreatic islets and endothelial cells in fibrin showed increased insulin secretion and 
preservation of islet integrity [125]. Culturing young porcine islets in fibrin exhibited the 
protective nature of fibrin towards hydrogen peroxide [126]. 
In addition to whole ECM proteins, functional peptides derived from the ECM can 
influence cell behaviour [127-130]. Peptide motifs from collagen I (GTPGPQGIAGQRGVV), 
collagen IV (MNYYSNS), fibronectin (PHSRN) and laminin (YIGSR) can enhance cell 
attachment [131, 132]. Arginine-glycine-aspartic acid (RGD), a peptide sequence found in 
fibronectin, vitronectin, laminin, collagen types I and IV, has a high affinity for integrin-mediated 
cell attachment and spreading, functionality and tissue development [133-137]. The RGD 
sequence co-immobilized with the SVVYGLR sequence was used to enhance the adhesion of 
endothelial cells[130]. Three ECM-derived peptides, laminin (IKLLI and PDSGR) and cadherin 
(HAVDI) supported the adhesion and survival of insulin-containing cultures for 5 days [129]. Rat 
insulinoma INS-1 cells cultured on immobilized ECM proteins and peptides (RGD & 
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CDPGYIGSR) showed higher glucose-stimulated insulin secretion compared to surfaces bearing 
no peptides [127]. 
Hyaluronic acid, a polysaccharide, helped in neuron survival and controlled self-renewal 
and differentiation of human embryonic stem cells [138, 139]. Many studies demonstrated that 
proteoglycans from the ECM are involved in molecular events of cell adhesion, proliferation and 
migration [140]. 
These are just examples of the effects ECM components can have on cells allowing for 
appreciating the potential impact of bioproducts made from decellularized tissues and organs. As 
reviewed by us and others, [118], [141] [142], other ECM proteins have been applied to produce 
biomimetic materials and surfaces and these include: collagen types I, III and IV, gelatin, 
fibronectin, vitronectin, polysaccharide nanofibers, proteoglycans, nidogen and laminins, as well 
as ECM-mimicking peptides including YIGSR,RGD, DGEA, KRSR, IKVAV, P15, and 
GFOGER, to list a few. 
Furthermore, following their implantation, decellularized scaffolds are repopulated by host 
cells and are even degraded, resulting in a functional tissue containing site-specific cells [143]. 
Decellularized tissues or organs, with or with no cells, can chemo-attract progenitor cells towards 
the implantation site [144, 145]. The degrading ECM molecules are also involved in various 
biological activities and growth factor signaling [146, 147]. Therefore, these matrices made from 
decellularized tissues and organs act as bioactive scaffolds by modifying the host environment to 
create a more suitable solution for healing, repair and even regeneration. 
ECM scaffolds made from decellularized tissues and organs also provide mechanical 
support in many conditions. They possess different physical characteristics, which are often 
difficult to reproduce with synthetic materials [148]. The ECM provides a mechanical support for 
the recellularizing cells to attach to the matrix. It is very important for scaffolds made from 
decellularized tissues and organs to have certain mechanical properties matching the site of 
implantation of the tissue or organ to be substituted. Creating less damage to the tissue during 
decellularization could yield better mechanical properties and more intact vasculature structure, 
facilitating the induction of angiogenesis post-implantation [44]. Also, the presence of ECM 
proteins and functional peptides in 3D scaffolds allows for recreating environments more 
physiological for cell culture, as opposed to traditional 2D cultures on flat surfaces. 
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2.6 Immunogenicity of ECM-based scaffolds 
 
Most decellularization protocols involve removing cell materials, which could cause major 
immunogenic reactions: hyperacute rejection, acute immune rejection, chronic immune rejection, 
and inflammatory reactions. Hyperacute rejection is a severe reaction of vascularized xenografts, 
triggered a few minutes to a few hours after implantation [149, 150]. This hyperacute rejection is 
mainly caused by the α-Gal epitope (galactose-α(1,3)-galactose) expressed on many cell surfaces 
and is less common in human and old-world monkeys. Pigs have been modified genetically to 
remove the Gal epitope to avoid xenograft rejections, but the application of this method is resulting 
into an acute immune rejection by non-Gal antibodies circulating at low levels, a few days to a few 
weeks after implantation [151]. Chronic immune rejection is associated with allograft 
transplantation by introducing donor-specific antibodies [152]. Also, the presence of DNA in 
decellularized tissues and organs can potentially cause inflammatory reactions [153]. 
Collagens with lower immunogenicity is achieved by removing N-and C- terminal 
telopeptides by pepsin type-I treatment, which are referred to as atelocollagen [154].  
Atelocollagens have been clinically applied in wound healing and as bone substitutes [154].  
Host response towards bioproducts made from ECM materials are different and are based 
on the product’s properties, species and methods of preparation; five different commercially 
available products were tested on rats and resulted in distinct morphological appearance of the 
implantation site[155]. Similarly, the immune reaction from the decellularized heart tissue 
(SynerGraft®) had a mixed reaction after implantation. In one study [156], SynerGraft® exhibited 
much less HLA (human leukocyte antigen) class I and II antibodies, as claimed by the company; 
however, in another study [117], macrophage infiltration after implantation was observed into the 
tissue decellularized using the SynerGraft® process [149]. In addition to that, porcine small 
intestinal submucosa had both positive and negative inflammatory responses when implanted into 
rodents [157-159]. 
Another important factor to be studied in detail is the response of host innate and adaptive 
immune response towards implanted xenograft materials. The polarization of T helper cells 1 
(Th1) and macrophages (M1) results in a pro-inflammatory response and T helper cells 2 (Th2) 
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and macrophages (M2) are involved in the anti-inflammatory response, which leads to constructive 
tissue remodelling[160]. 
Many studies have different conclusions on host-decellularized tissues/organs interactions and 
responses. Therefore, a detailed scientific understanding of the outcomes following decellularized 
product implantation including the responses of host tissues towards the implanted decellularized 
materials is vital [161]. 
2.7 Applications, status and perspective of decellularized tissues and 
organs 
 
Engineered substitutes could be a possible cure for patients in the last stage of tissue or organ 
failure. The increase demand for tissues and organs for transplantation and the encountered 
immune rejection of xenograft transplantations have pushed researchers to find alternative tissue 
and organ sources. 
Decellularized tissues and organs have a great potential to serve as carriers for transplanting 
autologous tissue made from the host cells or site-specific functional cells. Regardless of the 
availability of genetically engineered animals to harvest tissues or organs for transplantation, the 
rejection of the transplanted graft by the host appears inevitable [162]. This situation can 
potentially be solved with scaffolds and other bioproducts made from decellularized tissues and 
organs since antigenic elements of cell components are supposed to be completely removed. 
Recent advances involving recellularization of human-induced pluripotent stem cells in 
decellularized scaffolds could be a way to avoid the intake of immunosuppressive drugs required 
after organ transplantation [40, 163]. 
Achieving a functional tissue or organ is the goal of any decellularized scaffolds carrying 
either functional cells or stem cells. Failure of re-endothelialization of the organ with functional 
endothelium is one of the main reasons for organ loss in transplantation and a major hindrance in 
developing functional decellularized scaffolds. However, many studies have shown promising 
results on re-endothelialization and these could be considered as a potential solution to solve re-
endothelialization problems [164, 165]. 
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Materials and scaffolds made from decellularized tissues and organs have been 
commercially available for many applications. ECM-derived products from animal sources have 
been commercially available for more than 20 years and are applied in the treatment of many tissue 
regeneration processes and statistically, many years ago, over 200,000 patients have been 
implanted with xenogeneic decellularized scaffolds [166]. Many animal and human tissue-derived 
decellularized commercial products like Oasis® (porcine small submucosa, Cook Biotech, Inc., 
Indiana, USA), GraftJacket® (human dermis, Acelity L.P. Inc., Texas, USA), DermACELL® 
(human dermis, Novadaq Technologies Inc., Mississauga, Canada), Alloderm® (human dermis, 
Allergan plc (NYSE: AGN, Dublin, Ireland)), NeoFormTM (human dermis, California, USA), 
StratticeTM (porcine dermis, Allergan plc (NYSE: AGN, Dublin, Ireland)), RestoreTM (porcine 
small intestine (DePuy Orthopedics, Inc., Indiana, USA), PrimaTM Plus (porcine heart valve, 
Edwards Life Sciences LLC, California,USA), AlloSkin™ AC (human dermis, AlloSource, 
Centennial, CO, USA), MatriStem® (mucosa of urinary bladder, ACell, Columbia, USA), 
Biodesign® (small intestine, COOK MEDICAL INC., Bloomington, IN, USA), Lyoplant® 
(pericardium, Aesculap, Inc., Center Valley, PA, USA)[167, 168]. 
Most of the biological scaffolds are marketed as surgical mesh devices [168]. Scaffolds 
made from decellularized tissues or organs have the potential to be marketed under the category 
of 510(K) of the FDA (Food and Drug Administration) [169]. Under 510(K) clearance, a company 
must register to notify (PreMarket Notification or PMN) the FDA 90 days in advance of marketing 
a medical device. The FDA would assess the notified device to make sure it falls under the  already 
existing three classifications of devices in the market, for which a premarketing approval (PMA) 
is not required. The claim must be made by the company to support its device is substantially 
equivalent to the ones already available in the market. 510(K) devices can fall under 3 classes: 
class I, class II and class III, depending on the assurance of safety and effectiveness. 
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Table 2: Regulatory requirements for 510(k) devices [170]. 
Regulatory 
requirements 
Class I Class II Class III 
General controls 
All general controls 
are complied with and 
provide reasonable 
assurance 
General controls are 
insufficient to provide 
reasonable assurance 
General controls are 
insufficient to provide 
reasonable assurance 
Secondary controls 
No further secondary 
controls are required 
Information required 
to perform secondary 
controls are sufficient 
and hence secondary 
controls are 
performed for gaining 
reliable assurance of 
the device 
Information required 
to perform secondary 
controls are 
insufficient and hence 
secondary controls 
cannot be performed 
for gaining reliable 
assurance of the 
device 
Premarket 
notification/approval 
Eligible directly for 
premarket notification 
Eligible directly for 
premarket notification 
Requires premarket 
approval prior to 
notification 
Device/product risk Low Medium High 
 
Note: General controls refer to a comprehensive set of regulatory authorities to be complied for by 
any medical device to be marketed. Special controls are controls to be complied where general 
controls are insufficient. 
Oasis®, MiroMesh® and PhotoFix® are a few examples of 510(K)-cleared commercially 
available bioproducts derived from decellularized tissues and organs [167, 171]. 
Decellularized tissues which are intended to be implanted or transplanted have the potential 
to be marketed under the category Human Cells, Tissues, and Cellular and Tissue-Based Products 
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(HCT/Ps) of the FDA. HCT/Ps are products regulated by two different divisions, namely, the 
Center for Devices and Radiological Health (CDRH) & the Center for Biologics Evaluation and 
Research (CBER), or sometimes as a combination of both [172]. DermACELL® (a decellularized 
human dermis) and Allopatch HD® (an acellular human dermis) are examples of HCT/Ps products 
[167, 173]. Miromatrix Medical Inc. (Eden Prairie, Minneapolis), a USA-based biotechnology 
company founded in 2009, is involved in developing fully functional human organs by perfusion 
technology, primarily applied to the liver and, upon completion, extended to the kidneys. 
Miromesh™ and Miroderm™ (derived from porcine liver) are products launched by the company. 
AxoGen Inc. (Alachua, Florida) from the USA develops a technology to regenerate peripheral 
nerve injuries. AxoGuard® is derived from pigs and is used as a nerve connector. Another USA-
based company, Humacyte, Inc. (Morrisville, North Carolina), develops acellular grafts to repair 
vascular damages; some of their products are under Phase III clinical trials. 
2.8 Conclusions 
 
The selection of a technique or chemicals to decellularize a specific tissue or organ is an important 
decision to achieve complete decellularization and to retain intact the ECM. Perfusion 
decellularization has allowed fast and complete decellularization of many whole tissues and organs 
using either SDS or Triton X-100. Many whole organs have been successfully decellularized and 
subsequently seeded with different cell types. Recent advances in recellularizing decellularized 
tissues and organs involve the use of induced pluripotent stem cells to attain the native function of 
the tissue. Decellularized tissues or organs offer both mechanical support and cues from the ECM 
for cell growth and function in vivo. Many bioproducts derived from decellularized tissues and 
organs are commercially available, along with that, regenerative medicine companies are working 
to market functional whole organs to meet the demand. Extracting purified proteins from ECM or 
synthesizing new motifs are costly affairs compared to decellularizing a tissue, therefore, 
decellularized tissues and organs could be a potential source of substitutes for transplantation, 
provided they are devoid of cellular components, maintain the necessary functionality and are less 
immunogenic. 
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Chapter 3 
 
Decellularized pancreas as a native 
extracellular matrix scaffold for pancreatic islet 
seeding and culture 
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Titre en français : 
Pancréas décellularisé comme support naturel pour les îlots 
 
Résumé 
Le diabète se caractérise par une perte de fonction ou du nombre de cellules productrices 
d’insuline, les cellules-β, dans les îlots pancréatiques. La transplantation d’îlots est une des 
thérapies étudiées comme traitement du diabète, et des développements dans les méthodes 
d’ingénierie tissulaire peuvent améliorer la survie et la fonctionnalité des îlots transplantés. La 
transplantation des îlots les soumet à l’anoïkis, à l’hypoxie et aux attaques du système immunitaire, 
ce qui les fragilise et peut conduire à la destruction du greffon. Les avancées récentes en ingénierie 
tissulaire permettent d’utiliser des organes décellularisés comme supports aux cellules greffées. 
Le pancréas décellularisé pourrait être un bon support pour la transplantation d’îlots dans la mesure 
où l’on peut conserver correctement sa matrice extracellulaire (MEC) et son système vasculaire. 
Pour cette étude, le pancréas de souris a été décellularisé par perfusion d’une solution de 0,5% de 
dodecyl sulfate de sodium (SDS). Avec différentes techniques de caractérisation, nous montrons 
que le pancréas perd l’intégralité de ses cellules mais conserve une part importante de sa MEC. 
Des îlots isolés sont injectés dans le pancréas décellularisé via le canal collecteur et la 
fonctionnalité des îlots est confirmée par réponse à la stimulation au glucose (GSIS) après 48h. La 
re-cellularisation du pancréas par des cellules INS-1 exprimant la GFP montre que ce support est 
biocompatible et non-toxique après 120 jours. Ces données suggèrent que le pancréas décellularisé 
ensemencé par des cellules endocrines pourrait devenir un organe bioartificiel potentiellement 
utilizable dans le traitement du diabète. 
 
 
Mots clés : matrice extracellulaire; biomatériaux; pancréas décellularisé; fonction des îlots 
pancréatiques; pancréas bio-artificiel; cellules INS-1 marquées au GFP 
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Abstract 
 
Diabetes Mellitus involves the loss of function and/or absolute numbers of insulin-producing β-
cells in pancreatic islets. Islet transplantation is currently being investigated as a potential cure, 
and advances in tissue engineering methods can be used to improve pancreatic islets survival and 
functionality. Transplanted islets experience anoikis, hypoxia and inflammation-mediated immune 
response, leading to early damage and subsequent failure of the graft. Recent development in tissue 
engineering enables the use of decellularized organs as scaffolds for cell therapies. Decellularized 
pancreas could be a suitable scaffold as it can retain the native extracellular matrix (ECM) and 
vasculature. In this study, mouse pancreata were decellularized by perfusion using 0.5% sodium 
dodecyl sulphate (SDS). Different characterizations revealed that the resulting matrix was free of 
cells and retained part of the pancreas ECM including the vasculature and its internal elastic basal 
lamina, the ducts with their basal membrane as well as the glycosaminoglycan and collagen 
structures. Islets were infused into the ductal system of decellularized pancreata and glucose-
stimulated insulin secretion (GSIS) results confirmed their functionality after 48h. Also, re-
cellularizing the decellularized pancreas with GFP-tagged INS-1 cells and culturing the system 
over 120 days confirmed the biocompatibility and non-toxic nature of the scaffold. GFP-tagged 
INS-1 cells formed pseudo-islets which were, over time, budding out of the decellularized 
pancreata. Decellularized pancreatic scaffolds seeded with endocrine pancreatic tissue could be a 
potential bioengineered organ for transplantation. 
 
 
Keywords: extracellular matrix (ECM) scaffolds; pancreas decellularization; pancreatic islets 
functionality; bioartificial pancreas; GFP-tagged INS-1 cells; cell and islet seeding  
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3.1 Introduction 
 
Type-1 diabetes is caused by the autoimmune destruction of insulin-producing β cells of the 
pancreas [2]. These cells then can no longer produce insulin in response to glucose. Hence the 
patient depends completely on an exogenous supply of insulin to normalize the circulating blood 
glucose levels for long-term survival. A possible cure for type-1 diabetes came in 1966, when the 
first transplantation of a whole pancreas was successfully performed [174]. Akin to other major 
organ transplantation, whole pancreas transplantation continues to have morbid risks including 
surgical complications, post-op infection, technical failures, donor obesity which all influence the 
success and long-term graft survival [4]. The recipient also requires lifelong immunosuppressant 
drug administration. Given this, transplanting islets of Langerhans offers a less invasive, lower 
risk, alternative cure for type-1 diabetes. It reduces the overall post-surgical complications and 
improves the clinical outcome of the patient using immunosuppressant drugs [5, 6]. 
Over 1500 islet transplantation procedures have been carried out worldwide since 2000, but only 
approximately 7.5% of the transplanted patients remain insulin independent 5 years following  
transplantation [175, 176]. Current transplantation procedures involve the infusion of islets into 
the liver portal vein [177]. The major disadvantages of intraportal islet infusion are bleeding and 
thrombosis, while other factors like anoikis, hypoxia and inflammation-mediated immune 
response also result in impairment of islet function and graft loss [178-184]. 
Encapsulating islets could be a possible solution to protect the transplanted islets. The two main 
aims of encapsulating islets are to protect islets from the host immune response and to allow 
diffusion of molecules such as oxygen, nutrients, glucose, insulin and waste metabolites. Current 
research focuses majorly on two materials for encapsulation, namely, alginate and fibrin [185-
187]. The requirement to use poly-lysine to stabilise alginate gels results in decreased graft 
function in vivo [188]. Also, the use of high fibrinogen and thrombin concentrations to prepare 
fibrin gels has a negative impact on pancreatic islets [189]. Therefore, there is still a need to find 
suitable materials for encapsulation, which would more closely mimic the native environment of 
the pancreas and trigger acceptable and desirable host immune response. 
The pancreas extracellular matrix (ECM) has a big impact on islet biology apart from its physical 
structural support. The ECM mediates signalling for islets and β-cells survival, function, 
differentiation, proliferation and migration [190-194]. Scaffolds can be successfully obtained 
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following decellularization of organs and tissues [39, 63, 195-197]. A previous study on pancreatic 
scaffolds shows promising results in production and recellularization of a decellularized pancreatic 
tissue [42]. Encapsulating islets with ECM proteins has shown enhanced function of islets [198]. 
Implantation of cell-free decellularized pancreas proved to be a biocompatible scaffold by 
triggering angiogenesis in vivo after 14 days [44]. Therefore, we hypothesized that a decellularized 
pancreas, as scaffold to culture pancreatic islets, would create a favourable microenvironment for 
islet viability and functionality by preserving at least, part of the native pancreatic ECM. 
In this study, mouse pancreata were decellularized using 0.5% sodium dodecyl sulfate (SDS) 
infused through the ductal system. Separately, green fluorescent protein (GFP)-tagged INS-1 cells 
and pancreatic islets were perfused into the decellularized pancreas. Histological and 
immunohistochemical characterization, glucose-stimulated insulin secretion (GSIS) as well as 
scanning electron microscopy (SEM) and microscopic observations were performed to study in 
vitro the nature of the decellularized tissue and its influence on GFP-transfected cells and islets. 
 
3.2 Materials and methods 
 
3.2.1 Pancreas decellularization 
 
Mice (CD-1® IGS, Charles River, Boston, MA, USA) were sacrificed under a CO2 atmosphere, 
as approved by the Université de Sherbrooke’s ethical committee (protocol no. 367-14). A total of 
28 pancreata were used in this study. The full experimental procedure of the pancreas 
decellularization is presented in Figure 1 and as a supplemental video (Supplemental Video 1). 
The pancreas was injected with phosphate buffer saline (PBS) (BP6651, Fisher Scientific) through 
the pancreatic duct at the duodenal end using a 26-gauge needle. Reaching all sections of the 
pancreas using the needle during perfusion helps in obtaining a complete decellularization. Once 
the buffer reaches the entire pancreas, the needle was clamped along with the pancreas using a 
hemostat. The entire pancreas was mounted on a circulation system and the decellularization was 
achieved with a modified protocol which is described elsewhere [42]. Briefly, the pancreas was 
continuously perfused with 0.5% sterile SDS (616-0302, Biorad) using a Masterflex® L/S Easy-
Load II peristaltic pump at the flowrate of 8 mL min-1 for 12 h, then washed with sterile Milli-Q 
water for 15 minutes, followed by perfusing Milli-Q water containing benzonase (90 U mL-1) 
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(E1014, Sigma-Aldrich) for 15 minutes. The final wash was performed again with Milli-Q water 
for 15 minutes. Then, perfusion continued with PBS containing 10% FBS and a 
penicillin/streptomycin mix (10 000 U mL-1) (15140-122, Life Technologies) for 24 h followed by 
a final perfusion of Dulbecco Modified Eagle Medium (DMEM, D5523, low-glucose, Sigma-
Aldrich) containing 10% FBS and the penicillin/streptomycin mix for 36 h. 
 
 
 
Figure 1 Experimental procedures for pancreas harvesting and decellularization including cells 
and islets infusion as well as scaffold and cells/islets characterization. One full pancreas is used 
for decellularization and two for islet isolation 
 
3.2.2 Histological and immunohistochemical analyses 
 
The decellularized pancreata, with and without pancreatic islets, were fixed with 4% 
paraformaldehyde (PFA) (P6148, Sigma-Aldrich) overnight and processed in a tissue processor 
(Thermo Fisher Scientific, Shandon Citadel 1000). A standard procedure was followed for paraffin 
embedding and tissue sectioning [194]. The paraffin-embedded tissues were sliced to a 4-μm 
thickness and sections were stained with hematoxylin and eosin (H&E), alcian blue and nuclear 
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fast red. For immunohistochemistry, sections were deparaffinized and hydrated. Blocking was 
done using a blocking buffer (X0909, Dako) for 30 minutes at 370C and then incubated with 
monoclonal antibody (ab9569, Abcam) for overnight at 40C. Then, the sections were incubated 
with a secondary antibody (A11001, Abcam) for 1 h at room temperature and counterstained with 
4,6-diamidino-2-phenylindole, dihydrochloride (DAPI, D1306, Invitrogen). Sections were viewed 
and imaged under an epifluorescence microscope (Nikon Eclipse TE2000). 
 
 
3.2.3 Decellularized pancreas microstructure analysis by scanning electron 
microscopy (SEM) 
 
Samples were freeze-fractured and fixed with 2.5% glutaraldehyde in PBS (pH 7). After two 
washes with PBS (pH 7), the samples were fixed with 1% osmium tetroxide, then rinsed twice 
with distilled water. Dehydration was done with successive ethanol treatments prior to critical-
point drying with liquid carbon dioxide. The samples were mounted on stub and metal coated with 
gold/palladium and viewed via a Hitachi S-3000N scanning electron microscopy (SEM). 
 
3.2.4 Decellularized pancreas permeability by dye infusion 
 
Undiluted food colorant (propylene glycol & propylparaben) was added to the pre-clamped needle 
on a completely decellularized pancreas. The dye-containing solution was infused into the 
pancreatic duct by gravity. The entire process of dye infusion was video-recorded. 
 
 
3.2.5 Mouse islet isolation and islets infusion into decellularized pancreata 
 
Mice were sacrificed as mentioned earlier. The pancreas was infused through the duct with 
dissociation medium reconstituted with 2.5 mg mL-1 of collagenase (C9263, Sigma-Aldrich). The 
dissociation medium comprises L15 medium (L-4386, Sigma-Aldrich), 15mM HEPES, 10mM 
nicotinamide, 1 mg mL-1 glucose, 2% FBS, 0.35 mg mL-1 NaHCO3 and a penicillin/streptomycin 
mix. Then, the pancreas was removed and transferred into 15mL centrifuge tubes containing the 
same ice-cold mixture and incubated at 37oC in a water bath for 18±2 min with regular interval 
shaking. Ice-cold HBSS (H1387, Sigma-Aldrich) supplemented with 5% FBS, 10mM 
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nicotinamide, and 0.35 mg mL-1 NaHCO3 was added to stop the collagenase action. To avoid 
crowding of tissues while handpicking islets, a portion of digested tissues was transferred to 
bacteriological Petri dishes and diluted with HBSS. Islets were then picked using a 10µL 
micropipette under an optical microscope (Carl Zeiss, SteREO Lumar, between 6.5x to 80x) and 
stored temporarily in dissociation medium without collagenase. The isolated islets were re-
suspended in 250µL of islet medium, constituted with DMEM (D5523, low-glucose, Sigma-
Aldrich):RPMI (1:1), 5% FBS, 10mM nicotinamide, 15mM HEPES, and the same 
penicillin/streptomycin mix. Islets were injected very slowly into the decellularized pancreas using 
a 3mL syringe, which was connected with the 26g needle pre-clamped on the pancreas. 
Decellularized pancreata infused with islets were cultured in 12-well plates with islet medium for 
48 h. The percentage of islet retention inside the decellularized pancreas was calculated by 
subtracting the escaped islets from the initial number of islets infused. 
 
3.2.6 Glucose-stimulated insulin secretion (GSIS) 
 
GSIS assays were performed on decellularized pancreata containing islets and on islets in 
traditional tissue culture polystyrene (TCPS) plates. Samples were pre-incubated in 2.8mM 
glucose for 1h and then sequentially in: 1) 2.8mM, 2) 20mM, 3) 20mM + 50µM 3-isobutyl-1-
methylxanthine (IBMX, I5879, Sigma-Aldrich) and 4) 2.8mM, at 37°C and 5% CO2, in Krebs 
buffer made with 25mM HEPES, 115mM NaCl, 24mM NaHCO3, 5mM KCl, 1mM MgCl2 and 
0.1 % (w/v) bovine serum albumin. Insulin was measured after each incubation using a Mouse 
High Range Insulin ELISA (80-INSMSH-E01, Alpco). Since each decellularized pancreas 
contained a different number of islets, insulin concentrations were normalized to one islet. 
Performing GSIS on GFP-INS-1 cells-infused decellularized pancreata was not possible because 
of continuous formation and release of pseudo-islets from the matrix. 
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3.2.7 Seeding GFP-transfected INS-1 cells to assess cytocompatibility and cell 
distribution  
Lentiviral transfected GFP-INS-1 cells were cultured with DMEM [199]. Cells were trypsinized 
and re-suspended in 250µL of medium and injected into the decellularized pancreas using a 3mL 
syringe connected to the 26g needle pre-clamped on the pancreas. This experiment was done 
mainly to investigate cytocompatibility and to determine how long the matrix can support cell 
growth, as well as to evaluate cell distribution within the matrix. 
 
3.3 Results 
 
3.3.1 Pancreas decellularization 
 
The mouse pancreata were infused with 0.5% of SDS through the duodenal end of the ductal 
system. The complete process of decellularization takes ca. 12 h of perfusion. However, visible 
changes in color and size of the tissue can be observed from 2 h (Fig. 2). The infused solutions 
travel through the main duct and reach all parts of the pancreas. The total time taken for a dye to 
diffuse through the decellularized pancreas is approximately 7 min. 
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Figure 2 Pictures of the pancreas during decellularization over 12 hours. 
The different existing techniques of decellularization includes physical methods such as 
agitation in suspension, freeze-thaw cycles, vascular perfusion, as well as ultrasonic and manual 
disruption [200]. Chemical methods involve the use of detergents, solvents as well as acid, alkali, 
and ionic solutions while biological treatments use enzymes [110, 200, 201]. The greatest 
challenges among the previously mentioned techniques are to achieve maximal removal of cell 
debris and to retain the ECM components with minimal damage. The use of perfusion techniques 
has an edge over other techniques by minimizing the diffusion distance to achieve maximal 
decellularization in the shortest possible time period [42, 201]. SDS, an anionic detergent, 
effectively solubilizes both nuclear and cytoplasmic cellular membranes and several studies 
confirmed SDS to be effective in achieving maximal cell extraction with limited damage to the 
extracellular matrix [42, 72, 100, 116, 202]. The use of SDS (0.5%) for the purpose of 
decellularization has been reported in commercially available allogenic dermal graft [203]. The 
use of benzonase (endonuclease) helps removing nucleic acids by cleaving the mid nucleotide 
sequences [204]. Many studies reveal that benzonase is very effective in removing more than 99% 
of the DNA content from scaffolds [42, 110, 205]. 
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3.3.2 Characterization of decellularized pancreata 
 
Hematoxylin/eosin (H&E) and alcian blue/nuclear fast red staining revealed that the decellularized 
pancreas was completely free of cells and of nuclear materials. Eosin-stained collagen and alcian 
blue-stained glycosaminoglycans (GAGs) can be depicted in Figures 3B and 3D. A previous study 
that uses a similar technique of decellularization on mouse pancreas had similar H&E staining of 
the resulting scaffolds [42]. The metrics to define decellularization is the lack of visible nuclear 
material in tissue sections stained with H&E [110]. 
 
 
 
Figure 3 Hematoxylin/eosin (H&E) histological staining of (A) native pancreas and (B) 
decellularized pancreas. Alcian blue/nuclear fast red histological staining of (C) native pancreas 
and (D) decellularized pancreas. 
 
SEM analysis of the scaffold revealed that the decellularized pancreata were free of cells 
leaving only spaces left empty by the solubilized cells (Fig. 4C). Since our technique involves 
injecting the solution through the ductal system for decellularization, the vasculature system was 
not disturbed and appeared to be intact. The vasculature retained the internal elastic basal lamina 
as substantiated by its scalloped appearance, which confirms that the process of decellularization 
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was not too harsh and allowed for maintaining some microstructural aspects of the pancreas ECM 
(Fig. 4D) [42]. Laminin-rich basal lamina of the vasculature is involved in Rac activity and is 
known to promote the sprouting of endothelial cells [44, 206]. It can then be hypothesised that the 
formation of new blood vessels after implantation can be enhanced by preserving the vasculature 
ECM intact. In our study, the decellularization process removed the layer of ductal cells from the 
ducts, as seen in intact ductal system (Fig. 4B), leaving ducts with a layer of basal membrane (Fig. 
4E). SEM revealed that the 3D network of collagen fibers was retained from the decellularization, 
collagen being the most abundant protein of the pancreatic ECM (Fig. 4F) [207]. 
 
 
 
Figure 4 Comparison of native and decellularized pancreata by scanning electron microscopy 
(SEM). A) Clusters of pancreatic cells along with an ECM network. B) Intact duct with ductal 
cells (white arrow). C) Decellularized pancreas showing empty cellular spaces. D) Scalloped 
structure of inner wall of blood vessel. E) Basal lamina of decellularized ductal port. F) 
Structures showing collagen fibrils. 
 
3.3.3 Localization of infused pancreatic islets within decellularized pancreata 
 
The isolated islets were injected slowly into the main duct of the pancreas yielding a retention 
percentage of islets within the decellularized pancreas of approximately 70%. 
Immunohistochemistry analysis (Fig. 5B) revealed that the infused islets were not clumped 
together in the duct. Figure 5B also reveals that β-cells within the islets remain positive for insulin. 
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We believe that islets within the decellularized pancreas (Supplemental Fig. 1; Appendix A) were 
mainly located and attached to the ductal system. It has been reported in a previous study that some 
islets also move to the decellularized parenchymal matrix when they are infused through the ductal 
system [45]. Studies on pancreatic duct revealed the following information: i. the duct has close 
association with islets in adult rats, as most islets are connected to the ducts; ii. islet morphogenesis 
is influenced by ducts by budding out epithelial cells; and iii. ductal ECM contains laminin-1, 
fibronectin and collagen IV, which could improve β-cells survival [190, 208-210]. 
 
3.3.4 Functionality of pancreatic islets seeded within decellularized pancreata 
 
GSIS results confirmed that the islets were functional after 48 h of culture in decellularized 
pancreata. When compared to islets maintained in tissue culture polystyrene (TCPS) plates, islets 
in decellularized pancreata responded to glucose and secreted more insulin (Fig. 5A). However, 
comparing islets cultured in TCPS plates to those in 3D scaffolds, such as in decellularized 
pancreata, is difficult since the diffusional barrier is potentially affecting the GSIS response in 3D 
matrices [211]. Islets or β-cells cultured with ECM molecules showed improved survival and 
GSIS, by activating NF-κB signaling and integrin matrix interactions [187, 212-215]. Previously, 
decellularized pancreata were re-cellularized with human amniotic ﬂuid-derived stem cells and 
porcine islets [43], AR42J acinar cell line [42], MIN-6 β-like cells [42, 44], and rat islets [45]. In 
the particular study using porcine islets, the islets were seeded on decellularized pancreata and not 
within the organ. Also, islets functionality was not investigated [43]. An important finding from 
[45] is that the ductal system was the most efficient route for pancreas decellularization and 
subsequent islets infusion. But as the GSIS was carried out only immediately after infusing the 
islets into the decellularized matrix, the effect of the matrix on islets was not reported [45]. 
Although findings from those studies are of great importance, the use of decellularized pancreata 
to maintain islet functionality could not be confirmed. 
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Figure 5 (5A) Glucose-stimulated insulin secretion (GSIS) assay on islets maintained in tissue 
culture polystyrene (TCPS) plates and cultured in decellularized pancreata for 48 h. Insulin 
concentration given per islet. (5B) Immunohistochemistry staining positive for insulin and DAPI, 
Green - Insulin and Blue - DAPI.  
 
3.3.5 GFP-transfected INS-1 cells infused in decellularized pancreata 
 
GFP-INS-1 cells infused in the decellularized pancreas were maintained in culture for up to 120 
days, demonstrating that decellularized pancreata provide a cyto-compatible environment (Fig. 6). 
The metabolic activity of INS-1 cells and pancreatic islets were also determined (Supplemental 
Fig. 2; Appendix A). An observation was made during culture: individual cells formed pseudo-
islets (see Fig. 6F). The pseudo-islets were budding out from the matrix during the culture. Such 
behaviour with beta-like cells has never been reported. Although INS-1 cells proliferation was not 
quantified, as it is not possible to reliably estimate cell numbers because of constant release of 
cells from the decellularized pancreas, microscopic observations revealed that cells were 
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proliferating and forming pseudo-islets. A similar observation was made with pancreatic acini 
cells; when cultured on basal lamina, the cells rearranged into 3D acini-like structures and retained 
their differentiated morphology [216]. 
 
 
 
Figure 6 Green fluorescent protein (GFP)-transfected INS-1 cells (A) on a decellularized pancreas 
at Day 0. Cells were visible in the duct at (B) Day 3 and (C) Day 10. D) Cells at Day 60 forming 
pseudo-islets (indicated by white arrows). E) Cells at Day 120. F) Decellularized pancreas 
releasing pseudo-islets from the matrix (indicated by white arrows). 
 
3.4 Conclusion 
 
Decellularized pancreata can serve as a biocompatible scaffold to subsequently infuse pancreatic 
islets and are non-toxic and free of cellular components. They retain ECM and preserve inner 
vasculature structures. This study provided new insights on pancreas decellularization and its 
applications: 1. A new technique has been adapted to perform perfusion decellularization of whole 
pancreata and subsequent seeding of pancreatic cells and islets without the need to dismantle the 
organ from the perfusion system; 2. A GSIS analysis on infused islets after 48h of in vitro culture 
demonstrated for the first time that infused islets remain functional into decellularized pancreata; 
3. Cytocompatibility has been shown with beta-like cells for 120 days in vitro, opening new 
windows of opportunity for stem cell culture and differentiation for longer period; 4. Beta-like 
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cells cultured in decellularized pancreata formed pseudo-islets and were budding out of the matrix; 
and 5. Decellularized pancreata could serve as an ECM scaffold “bag” to carry islets for 
transplantation. This study goes one step closer to in vivo testing, as this method could be an 
innovative approach in developing a bioartificial pancreas for transplantation. 
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Chapter 4 
 
Solubilisation of decellularized pancreata and 
immobilization on low-fouling surfaces for islet culture  
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Titre en français : 
Solubilisation de pancréas décellularisés et immobilisation sur des surfaces à faible encrassement 
pour la culture d’îlots pancréatiques 
Résumé  
 
La matrice extracellulaire (MEC) joue un rôle important dans la physiologie des îlots de 
Langerhans. Ainsi, l’étude d’îlots sans leur MEC native peut conduire à des erreurs d’interprétation 
de leur fonctionnement. Des surfaces biomimétiques ont été préparées à partir de molécules de la 
MEC de pancréas de souris décellularisés et de MEC solubilisée suivant trois méthodes distinctes 
(pepsine, acide acétique et NaOH). Ces trois méthodes ont permis une solubilisation allant de 
partielle à totale. Les extraits de pancréas décellularisés ont été greffés sur des surfaces à faible 
adhérence et mis en culture avec des îlots. Des cellules ont migré à l’extérieur des îlots sur toutes 
les surfaces sauf sur celles anti-adhérentes. Différentes morphologies de cellules ont été observées. 
Les îlots cultivés sur ces surfaces étaient viables et fonctionnels après 5 jours de culture, sauf pour 
les surfaces greffées avec les extraits solubilisés avec le NaOH qui montrèrent une certaine 
toxicité. 
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Abstract 
 
Investigating islets without their native extracellular matrix (ECM) may lead to aberrant responses. 
Biomimetic surfaces were prepared from ECM of decellularized mouse pancreata solubilized 
using pepsin, acetic acid or NaOH. All three methods resulted in solubilisation. Decellularized 
pancreata were grafted on low-fouling surfaces to support mouse islets. Cell outgrowth from islets 
was observed on all surfaces except for low-fouling surfaces. Differences in cell morphology on 
biomimetics were noted. Islets were functional and viable after 5 days, except on NaOH-
solubilized extracts, which exhibited some cytotoxicity. This study reports for the first time the 
solubilisation of a decellularized pancreas and its immobilization on low-fouling surfaces. 
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The extracellular matrix (ECM) plays an important role in islet biology. Losing the ECM during 
isolation of islets aimed for clinical transplantation results in rapid anoikis of islets (within 48h) 
[183]. The ECM is synthesised by the native cells, is mainly involved in mechanical support and 
provides cues for cell migration, attachment, differentiation and function [8, 9]. It is necessary to 
appreciate the importance of the ECM in islet behaviour to maintain these islets healthy. 
Considering the importance of the ECM and its role in islets viability and functionality, culturing 
islets on tissue culture polystyrene (TCPS) can result in false interpretations masking the islets 
responses towards the targeted treatment. Comparisons of results obtained with TCPS and surface-
immobilized ECM proteins/peptides highlight the influence of the ECM on islets insulin secretion 
and viability [127, 129]. 
ECM proteins as well as ECM-derived peptides can have various positive effects on islets 
and beta cells. Culturing rat islets on fibronectin improved proliferation and prevented apoptosis 
[217, 218]. Laminin-derived (IKLLI and PDSGR) and cadherin-derived (HAVDI) peptides 
supported the adhesion and survival of dissociated pancreatic islets for 5 days [129]. The integrin-
binding tripeptide RGD sequence found in type I collagen, laminin, fibronectin, vitronectin and 
fibrinogen improved the survival and function of rat insulinoma beta cells (INS-1 cells) in vitro 
[127]. Culturing human islets on ECM proteins like collagen (types I and IV), fibronectin, and 
laminin had a positive influence on cell attachment, insulin secretion and cell survival [219]. In 
addition, islets cultured in 3D fibrin gels are more functional in vitro and in vivo than in 2D [220]. 
The re-establishment of the lost pancreatic ECM environment can contribute to islets 
function and survival in vitro, a step closer to producing an in vivo-mimicking environment. A 
decellularized pancreas incorporates ALL of the individual proteins/peptides that make up the islet 
ECM. Decellularized pancreas immobilized on a surface thus more closely represents a true 
biomimetic interface in comparison to previous studies that analyze individual proteins/peptides. 
Also, studies on individual proteins/peptides have shown positive results, however, studies on 
combination of these proteins/peptides can be costly. Extracting the ECM from the pancreatic 
tissue would be of great interest to design biomimetic materials. Various studies involving 
solubilization of pancreatic ECM were performed, highlighting the importance of ECM in 
regenerative medicine [42, 221, 222]. 
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In the present study, biomimetic surfaces were prepared from decellularized mouse 
pancreata solubilized by three methods: pepsin digestion, acetic acid and NaOH. Decellularized 
pancreatic extracts were grafted on low-fouling carboxymethyl-dextran (CMD) surfaces to limit 
non-specific interactions between the islets and the underlying TCPS surface. Pancreatic mouse 
islets were isolated and cultured on these biomimetic surfaces for 5 days. Cell attachment and 
morphology, cell viability and glucose-stimulated insulin secretion (GSIS) were investigated to 
screen the effects of the biomimetic surfaces on islets. 
Complete pancreas decellularization was achieved, as described in the section 3.2.4, by 
perfusing 0.5% sodium dodecyl sulfate (SDS) through the duodenal end of the ductal system [223]. 
Perfusion decellularization with SDS through ductal system of the pancreas eliminates almost all 
cellular components [223]. Decellularized pancreata were frozen overnight at -80°C and freeze-
dried for 48h. The freeze-dried samples were finely chopped into tiny pieces, before solubilisation. 
The samples (1 mg mL-1) were solubilized using three methods: 1. pepsin digestion (1 mg mL-1 in 
0.01M HCl at 370C for 48h), 2. 0.01M acetic acid for 48h at 370C under agitation at 60 rpm, and 
3. 1M NaOH for 15 min at 60°C in a water bath. NaOH and acetic acid resulted in complete 
solubilisation of pancreata, while pepsin digestion resulted in partial solubilisation (Supplemental 
Fig. 3; Appendix A). Once solubilisation/digestion was completed, the sample pH was adjusted at 
around 5.5 and then immobilized on CMD surface to culture islets since the isoelectric point of 
unpurified collagen is approximately pH 5.8 [224]. The islet culture was performed at pH 7. 
The protein content of the solubilised decellularized pancreata was estimated using a 
Bradford protein assay kit (protein assay kit, 500-0006, Bio-Rad), using the microassay procedure 
for microtiter plates and the absorbance was measured at 595nm [225]. Different methods of 
solubilization could yield different compositions of proteins [226, 227]. 
Protein content of the three extracts was estimated (Fig. 7). NaOH solubilisation yielded 
the highest protein/peptide content (ca. 1.2 mg mL-1 from a 10 mg mL-1 solution of decellularized 
pancreas), as compared to the acetic acid treatment and pepsin digestion. 
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Figure 7. Protein content estimated by a Bradford protein assay of decellularized pancreata 
solubilised by pepsin, NaOH and acetic acid. 
 
Synthesis of carboxylmethyl-dextran (CMD) has been described elsewhere [128]. 96-well 
tissue culture polystyrene (TCPS) plates were first modified by plasma polymerization of n-
heptylamine to introduce functional amine groups [228]. CMD was grafted on the n-heptylamine-
functionalized surfaces, as described elsewhere [130]. The CMD-grafted surfaces were rinsed with 
1M NaCl twice at an interval of 12h and then followed by rinsing with Milli-Q water twice at an 
interval of 12h. After rinsing, the surfaces were sterilized under UV for 20 min and stored in Milli-
Q water at 4°C until use. CMD surfaces have excellent low-fouling properties towards many cell 
types and proteins, allowing for better discrimination of the effects of the molecules of interest 
[127]. 
Surface-immobilization of solubilised pancreata was carried out by activating for 10 min 
the CMD surfaces with 200mM of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)/N-
hydroxysuccinimide (NHS) in sterile solutions and under agitation at room temperature. Activated 
CMD surfaces were then rinsed twice with sterile Milli-Q water [127, 229]. Solutions from 
decellularized pancreata (100 μL/well) containing 30µM of CaCl2 [229] were added and plates 
were incubated for 3h at 37°C under agitation (70 rpm). After incubation, the surfaces were rinsed 
with sterile PBS and utilized immediately. All procedures for surface-immobilization were done 
under aseptic conditions. 
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Small pieces (ca. 1cm in radius) of tissue culture polystyrene (TCPS) from 6-well plates 
bearing the different layers were sent for X-ray photoelectron spectroscopy (XPS) analysis, as 
described elsewhere [128]. Three different spots on each surface were analysed. 
All the surfaces were analysed by XPS (Table 3). Atomic ratios of the elements are determined 
from survey spectral analysis. There was an increase in nitrogen content of all biomimetic surfaces 
compared to CMD surfaces, the latter incubated in Milli-Q water at 40C for 2 weeks. Similarly, an 
increase in N/C ratios was seen for the biomimetic surfaces. It is difficult to confirm grafting of 
decellularized pancreatic extracts using XPS high-resolution spectra [128] (presented in 
Supplemental Fig. 4; Appendix A). There was no augmentation in the binding energy at 288-289 
eV (peptide bonds) on all surfaces bearing ECM extracts when compared to CMD surfaces. The 
breakdown of proteins into small peptide fragments during solubilisation could be a possible 
reason for the unreliable XPS high resolution spectra detection, as previously reported 3,[128]. 
Confirmation of surface-grafted peptides, given their small size, needs to be complemented by a 
cell test. 
Table 3. X-ray photoelectron spectroscopy (XPS) atomic concentration (%) and atomic ratios of 
the different surfaces obtained from XPS survey spectra. 
 
 
Atomic concentration (%)  Atomic ratio 
O 1s C 1s N 1s O/C N/C N/O 
n-heptylamine 
plasma polymer 
surfaces 
1.37 
(± 0.09) 
90.52 
(± 0.19) 
8.06 
(± 0.19) 
0.01 0.08 5.85 
CMD surfaces in 
Milli-Q water at 
4oC for 2 weeks 
16.88 
(± 0.16) 
79.57 
(± 0.40) 
3.11 
(± 0.39) 
0.21 0.03 0.18 
Biomimetics 
bearing pepsin 
extracts 
18.97 
(± 0.70) 
75.77 
(± 0.82) 
4.58 
(± 0.04) 
0.25 0.06 0.24 
Biomimetics 
bearing NaOH 
extracts 
18.76 
(± 0.45) 
75.81 
(± 0.80) 
4.42 
(± 0.40) 
0.24 0.05 0.23 
Biomimetics 
bearing acetic 
acid extracts 
18.85 
(± 0.61) 
75.58 
(± 1.02) 
4.73 
(± 0.40) 
0.24 0.06 0.25 
Pepsin control 
surfaces 
14.71 
(± 0.04) 
80.59 
(± 0.15) 
4.48 
(± 0.11) 
0.18 0.05 0.30 
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Islets were isolated as described in section 3.2.5. Each condition comprised 20 islets with 200μL 
of medium/well in a 96-well plate. 
As described in the section 5.2.6, viability was assessed at the end of the GSIS assay. A 
GSIS assay was performed on islets after 5 days in culture on the different biomimetic and control 
surfaces. As described elsewhere, samples were pre-incubated with 2.8mM glucose for 1h and 
then sequentially with: 2.8mM, 28mM, 28mM + 50µM 3-isobutyl-1-methylxanthine (IBMX, 
I5879, Sigma-Aldrich) and 2.8mM at 37°C and 5% CO2 [127]. Solutions were collected after each 
incubation and stored at -20°C. Insulin in the solutions was measured using a Mouse High Range 
Insulin ELISA assay (80-INSMSH-E01, Alpco). 
 
 
 
 
 
 
 
 
 
 
Figure 8. Microscopic images of islets after 5 days of culture on a CMD low-fouling layer, TCPS 
and a pepsin control surface (i.e., “pepsin control surfaces” refer to activated CMD surfaces 
incubated in a solution with only pepsin without decellularized pancreata, to check the effect of 
immobilized pepsin on cells) and on the biomimetic surfaces bearing decellularized pancreatic 
extracts obtained from acetic acid, NaOH and pepsin treatments. 
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Islets morphology in all conditions at Day 5 is shown in Figure 2. CMD surfaces retained 
their low-fouling properties, as illustrated by the absence of islets attachment to the surface. 
However, over time, islets tended to aggregate (Fig. 8). Islets on TCPS started attaching to the 
surface from Day 3 and cell outgrowth was subsequently observed; cells seen on the surface appear 
fibroblastic at Day 5 (Fig. 2). Islet attachment and cell outgrowth were observed sooner, from Day 
1, on surfaces bearing acetic acid- and pepsin-solubilised pancreata. However, the cell morphology 
was very different than that observed on TCPS at Day 5 (Fig. 8). On surfaces bearing NaOH-
solubilised pancreata, cell attachment was observed, but to a lesser extent, compared to surfaces 
made with acetic acid- and pepsin-treated pancreata. Also, dissociation of islets was observed with 
NaOH-solubilisation (Fig. 2). Little cell attachment was seen on pepsin control surfaces (Fig. 2). 
Not all islets are spheroidal and islet shape alone cannot be considered as a sign of distress of islets; 
difference in the isolation process and animals could explain variation in insulin release [230-232]. 
Islet morphology at Day 0, 1 and 3 on all surfaces are shown in Supplemental Figures 5-7; 
Appendix A. 
In all conditions, islets secreted insulin in response to glucose after 5 days of culture 
(Supplemental Figs. 8-9; Appendix A). Overall, insulin secretion in response to glucose was higher 
on islets cultured on the biomimetic surfaces when compared to those on CMD and TCPS 
(Supplemental Figs. 8-9; Appendix A). The stimulation indices calculated from the ratio of the 
insulin concentration at high-glucose + IBMX concentration to that at high-glucose concentration 
confirm islets are responding to IBMX (Fig. 9). With the stimulation indices calculated from ratios 
of insulin concentration at high glucose to that at low glucose, it is difficult to conclude on islet 
functionality (Supplemental Figs. 10; Appendix A). Ratios of insulin concentration at last low-
glucose concentration to that at first low-glucose from glucose-stimulated insulin secretion (GSIS) 
assays revealed that islets responded to glucose gradients and returned to basal secretion levels 
(Supplemental Figs. 11; Appendix A). 
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Figure 9. Stimulation indices (ratio of insulin concentration at high glucose-IBMX concentration 
to that at the high-glucose) from glucose-stimulated insulin secretion (GSIS) assays on murine 
islets cultured on the different surfaces 
Live/dead staining revealed that islets cultured on all surfaces, except those produced from 
NaOH-solubilised pancreata, were viable after the GSIS assay at Day 5 (Fig. 4). In addition to the 
observed low level of insulin secreted from islets cultured on biomimetic surfaces made with 
NaOH soluble extracts, islets viability was lower for that condition (Fig. 4). This observed 
cytotoxicity was reported earlier, when skin was decellularized by NaOH [114]. We hypothesize 
that NaOH toxicity could have resulted from an insufficient washing of the surfaces. 
 
 
 
 
 
 
 
 
Figure 10. Viability of islets cultured on the different surfaces after a GSIS assay, by staining with 
fluorescein diacetate (live - green) and propidium iodide (dead - red). 
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To conclude, decellularization of mouse pancreata followed by ECM solubilization was achieved 
using three solubilization protocols. These solubilized ECM contents were immobilized on CMD 
surfaces. Isolated mouse islets were cultured successfully for five days on biomimetic surfaces and 
remained viable for the culture period. Their functionality was retained partially. NaOH 
solubilization yielded the highest protein content but the resulting surfaces were cytotoxic as 
compared to the other surfaces made of pepsin and acetic acid extracts. Surfaces bearing ECM 
contents resulted in higher insulin secretion compared to the control surfaces (TCPS and CMD). 
Characterization of the solubilized proteins from the ECM and the different cell types from the 
islets found on surfaces will be performed in future studies. This work reports, for the first time, 
the solubilisation of a decellularized pancreas and its successful immobilization on low-fouling 
surfaces. 
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Chapter 5 
 
Insulin secretion kinetics from single islets 
reveals distinct sub-populations  
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Titre en français : L’analyse du profil cinétique de sécrétion d’insuline par des îlots uniques 
montre l’existence de populations distinctes d’îlots. 
 
Résumé 
 
Le diabète de type II évolue avec une sécrétion d’insuline inadéquate et une augmentation de 
l’exposition à un taux élevé de glucose dans le sang. In vitro, la sécrétion d’insuline par les îlots 
en réponse à la stimulation par le glucose suggère que tous les îlots ne répondent pas de façon 
équivalente. Nous faisons donc l’hypothèse que tous les îlots isolés du pancréas ne sécrètent pas 
l’insuline de manière unique. Pour vérifier cette hypothèse, nous avons mesuré et modélisé la 
cinétique de sécrétion d’insuline sur des îlots individuels, isolés de pancréas de souris, et soumis à 
une stimulation chronique au glucose (2.8-20 mM). L’analyse cinétique sur 58 îlots distincts 
exposés 72h à une concentration élevée en glucose montre l’existence de différents profils de 
sécrétion : lent, rapide, et sécrétion à taux constant ; le profil de sécrétion lent étant le plus observé 
(50%). Il existe donc une variation temporelle dans la réponse au glucose. Lors de courtes 
expositions (<4h) à un taux élevé de glucose, très peu d’îlots réagissent pas une sécrétion d’insuline 
maintenue dans le temps. Ce modèle permet également d’analyser l’influence de la taille des îlots 
sur la sécrétion d’insuline, sans montrer d’effet clair de ce paramètre. Pour une forte concentration 
en glucose, la quantité d’insuline sécrétée normalisée par rapport au volume de l’îlot montre une 
tendance de sécrétion plus grande par les îlots de petite taille. De plus, pour des concentrations 
élevées en glucose, la sécrétion d’insuline mesurée sur des îlots individuels est similaire à celle 
mesurée pour des populations d’îlots, tandis que pour des concentrations faibles en glucose, nous 
n’observons pas les mêmes profils de sécrétion pour les îlots individuels et les groupes d’îlots. 
 
 
Mots clés : modélisation de la sécrétion; concentration de glucose; îlots individuels; taille d’îlots; 
sécrétion rapide; sécrétion lente; sécrétion à taux constant 
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Abstract 
 
Type II diabetes progresses with inadequate insulin secretion and prolonged elevated circulating 
glucose levels. Also, pancreatic islets isolated for transplantation or tissue engineering can be 
exposed to glucose over extended timeframe. We hypothesized that isolated pancreatic islets can 
secrete insulin over a prolonged period of time when incubated in glucose solution and that not all 
islets release insulin in unison. Insulin secretion kinetics was examined and modeled from single 
mouse islets in response to chronic glucose exposure (2.8-20mM). Results with single islets were 
compared to those from pools of islets. Kinetic analysis of 58 single islets over 72h in response to 
elevated glucose revealed distinct insulin secretion profiles: slow-, fast- and constant-rate 
secretors, with slow-secretors being most prominent (ca. 50%). Variations in the temporal response 
to glucose therefore exist. During short-term (<4h) exposure to elevated glucose, few islets are 
responding with sustained insulin release. The model allowed studying the influence of islet size, 
revealing no clear effect. At high-glucose concentrations, when secretion is normalized to islet 
volume, the tendency is that smaller islets secrete more insulin. At high-glucose concentrations, 
insulin secretion from single islets is representative of islet populations, while under low-glucose 
conditions pooled islets did not behave as single ones. The characterization of insulin secretion 
over prolonged periods complements studies on insulin secretion performed over short timeframe. 
Further investigation of these differences in secretion profiles may resolve open-ended questions 
on pre-diabetic conditions and transplanted islets performance. This study underlines the 
importance of size of islets in insulin secretion. 
 
Key words: insulin secretion modeling; glucose concentration; single islets; islet size; fast 
secretors; slow secretors; constant-rate secretors.
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5.1 Introduction 
Isolated pancreatic islets are used to perform studies on islet biology, tissue engineering 
methods and transplantation as well as on diabetes. Islets exist in different sizes throughout the 
pancreas. In vitro, it is believed that the rate of insulin secretion is proportional to the size of the 
islets but some studies revealed that smaller islets secrete more insulin than larger ones. Smaller 
islets are believed to have a larger number of β-cells relative to the other cell types and higher 
oxygen diffusion [233-237]. Those studies often involve the stimulation of islets with a single 
glucose concentration and only for a few hours (up to 2h). 
Many studies involving glucose-stimulated insulin secretion (GSIS) show that the 
exocytosis of cytoplasmic insulin granules occurs in a biphasic manner both in vitro and in vivo. 
This was first reported in 1968.[238-241] The first phase of insulin release occurs within 1 to 10 
minutes by the pre-docked insulin granules at the plasma membrane from a readily releasable pool 
(RRP). The granules from the reserve pool, which lies further from the plasma membrane, are used 
to refill the RRP [239, 242] and this constitutes the second phase. This secondary release is slow 
and sustained as long as glucose concentration remains high.[239, 243, 244] 
A slowdown in both first and second phases of glucose-stimulated insulin secretion is 
considered to be an early indication of β-cells dysfunction in type-2 diabetes [240]. Investigating 
insulin and glucose relationship is important but this is hard to perform in vivo since direct 
detection of insulin is difficult and insulin degradation is fast (4-6 min) [245]. When investigated 
in vivo, kinetics of insulin secretion in response to glucose has been carried out often for short 
periods of time (0 to 2h) [246, 247] and has demonstrated that not all islets secrete in unison [248]. 
During and after isolation, islets undergo physical, enzymatic and chemical damages 
leading to functional loss [249]. The most common practice to evaluate islet function is the GSIS 
assay that investigates insulin secretion in a static manner. A GSIS assay takes a “snapshot” of the 
insulin released following a short period of time following islet incubation in glucose solutions. 
Typically, insulin is measured from the same population of islets after a series of one-hour 
incubations in different glucose conditions. Glucose concentrations used in GSIS assays can vary 
between studies. GSIS assays currently applied represent modified versions of the erstwhile 
functionality experiment reported in 1967 on isolated rat islets, wherein functionality was 
determined by incubating the islets with 1.6mM and 16.6mM glucose in Krebs bicarbonate 
solution and the insulin release was measured over 90 minutes in vitro [250]. Pancreatic islets 
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isolated for transplantation or tissue engineering can be exposed to high glucose concentrations 
over extended periods of time, both in vitro and in vivo. 
Practically, batch-to-batch variability of tissues and enzyme cocktails used in isolation, low 
isolation yields, large number of required animals as well as animal variation, when non-human 
tissues are utilized [251, 252], are all imposing a financial burden on the usage of islets. 
Considering that few islets can be obtained from each isolation from mice (typically, 200 to 250 
islets per mouse; in our laboratory around 150),[253] there is a need to develop models that would 
use fewer islets per condition. 
The objective of this work was to model the insulin secretion profile to categorize islet sub-
populations by developing and using an assay investigating insulin secretion kinetics from isolated 
single islets. The responses of single islets were also compared to those of pooled islets. Single 
islets refer here to one islet per culture well as opposed to pooled islets (10 islets) which correspond 
to 10 islet equivalents per culture well. In addition, the effect of islet size and glucose concentration 
on the kinetics of insulin secretion was studied. To reach these goals, the kinetics of insulin 
secretion from isolated single islets exposed to four glucose concentrations were investigated for 
a period of 72h and compared to those of populations of 10 islets. 
 
5.2 Materials and methods 
 
5.2.1 Mouse islet isolation 
 
Female mice between 19g and 33g (CD-1® IGS, Charles River, Boston, MA, USA) were 
sacrificed under a CO2 atmosphere, as approved by the Université de Sherbrooke’s ethical 
committee (protocol no. 367-14). The pancreata were injected with a dissociation solution 
containing 0.5 mg mL-1 of collagenase (C9263, Sigma-Aldrich, Oakville, ON, Canada). 
Dissociation solution was composed of L15 medium (L-4386, Sigma-Aldrich), 15mM HEPES, 
10mM nicotinamide, 1 mg mL-1 glucose, 2% (v/v) FBS, 0.35 mg mL-1 NaHCO3 and a penicillin 
(100 U mL-1)/streptomycin (100 µg mL-1) mix. Then, the pancreata were excised and transferred 
to 15 mL centrifuge tubes containing the same ice-cold mixture (for transportation) and incubated 
for 18±2 min in a 37°C water bath with regular interval shaking. Digestion was stopped by adding 
ice-cold HBSS (H1387, Sigma-Aldrich) supplemented with 5% (v/v) FBS, 10mM nicotinamide, 
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and 0.35 mg mL-1 NaHCO3. Digested tissues were split in bacteriological Petri dishes and diluted 
with HBSS solution. Islets were then recovered by handpicking under an optical microscope (Carl 
Zeiss, SteREO Lumar. V12, between 6.5X to 80X) and placed in dissociation medium without 
collagenase. 
 
5.2.2 Islet culture 
 
Isolated islets were pre-incubated in RPMI 1640 (R1383, Sigma Aldrich) without glucose, 
supplemented with 10mM nicotinamide, 15mM HEPES and the penicillin/streptomycin mix, for 
30 min at 37°C and 5% CO2. For each experiment, islets were cultured in 1 mL of growth medium 
in 24-well plates containing either 2.8mM, 5.6mM, 11.2mM, or 20mM glucose. Growth medium 
was DMEM (D5523, low-glucose, Sigma-Aldrich):RPMI (1:1), with 5% (v/v) FBS, 10mM 
nicotinamide, 15mM HEPES, and the penicillin/streptomycin solution. Islets were counted, before 
and after sampling, to ensure islets were not accidentally removed during pipetting. Pictures were 
taken at 4X and 10X (Nikon Eclipse TE2000) to measure islet sizes using the ruler tool in Adobe 
Photoshop®. For spherical islets, the diameter was calculated by taking the mean of the biggest 
and smallest diameter of each islet. For those which were oval or cylindrical, mean diameters were 
estimated from the volume of a sphere equal to that of an ovoid or a cylinder determined from the 
respective formula for calculating volume and representing the corresponding islet.[128] 
Conversion between pixels and micrometer was performed using a scale previously established 
using pictures of a ruler at each magnification of the microscope. Islet equivalent was obtained by 
dividing the mean diameter by 150µm.[254] For ten islets (picked randomly), the total mean 
diameter was divided by 150µm. 
 
5.2.3 Measurements of insulin secretion 
 
Medium samples were collected at different time points for ELISA to test the insulin 
secretion. As described in the manuscript, one islet or ten islets were both incubated in 1 mL 
medium, resulting in the big difference in cumulative insulin concentration in the medium (Fig. 
1A). Cultures were incubated for 72h and media (25 µL each) were collected over 8 time points 
(0.5, 1, 2, 4, 18, 24, 48 and 72 hours) under the microscope (SteREO Lumar. V12) to avoid picking 
68 
 
islets during collection. Insulin concentrations were corrected for volume sampling. Triplicates for 
each culture condition were performed. Insulin in the media was measured using an ELISA kit 
(80-INSMSH-E01, Mouse High Range Insulin ELISA, Alpco, Salem, NH, USA). 
 
5.2.4 Modeling of insulin secretion 
 
Insulin secretion was modeled from 58 single islets isolated from five mice and from 36 10-islet 
pools obtained from 9 mice (Fig. 11A). Considering the shape of the insulin secretion curves over 
time (Fig. 11 for typical examples), islets were categorized as Fast Secretors (Equation 1, first-
order function), Slow Secretors (Equation 2, second-order function), or Constant-rate Secretors 
(Equation 3, linear regression (zero-order function)). Equations 1-3 were therefore used to fit the 
data. Full development of Equations 1 and 2 is presented in Supplemental Materials. 
 
 
𝑦 = 𝐾𝑃𝐴(1 − 𝑒
−𝑡 𝜏𝑝⁄ ) Equation 1 (Fast secretors) 
 
𝑦 = 𝐾′𝑝𝐴 [1 −
1
(𝜏2− 𝜏1)
(𝜏1 𝑒
−𝑡 𝜏1⁄ − 𝜏2 𝑒
−𝑡 𝜏2⁄ )] Equation 2 (Slow Secretors) 
 
y is the insulin concentration in function of time in ng mL-1, t the time in hours, 𝐾𝑝 and 𝐾′𝑝 are the 
steady-state process gains in (ng of insulin/mL) (mM glucose)-1, A the step input (i.e., the glucose 
concentration in which islets are incubated) in mM of glucose, τp is the time constant in hours for 
first-order systems, and τ1 and τ2, the two time constants for second-order systems in hours. The 
𝐾𝑝𝐴 or 𝐾′𝑝𝐴  product represents the asymptotic (at plateau) value of cumulative insulin 
concentration in ng mL-1. 𝐾𝑝 and 𝐾′𝑝 can be interpreted as the ratios of the predicted (modeled) 
cumulative insulin concentration at plateau to the glucose concentration used to incubate the islets. 
 
𝑦 = 𝑚𝑡 Equation 3 (Constant-rate Secretors) 
 
m is the rate of insulin secretion in ng mL-1 h-1 and t the time in hours. 
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τp and 𝐾𝑝 as well as τ1, τ2, and 𝐾′𝑝 were obtained after minimizing the sum of the squared errors 
with the Excel 2013 solver. For most curves, the function selected to fit the experimental points 
was that giving the best mathematical fit (i.e., the smallest error), but for some systems a visual 
inspection was also done to complement the mathematical fitting strategy to make sure that the 
trend of the experimental points was respected. 
With a fast secretor (Fig. 11B), the insulin released increases rapidly at first (represented 
by τp in Eq. 1) and then gradually approached a steady state (plateau) concentration (𝐾𝑝𝐴 in Eq. 
1). In particular, the initial rate of release was characterized by an exponential function. Whereas 
with a slow secretor (Fig. 11C), the behaviour can be described by two (first-order) processes in 
series. Firstly, the concentration increases at a rate that can be represented by a first-order dynamic 
(τ1 in Eq. 2). Then, it goes through another secretion phase that can be described by a second first-
order function (τ2 in Eq. 2). Finally, it levels off to a steady state (at plateau) value (𝐾′𝑝𝐴 in Eq. 
2). With a constant-rate secretor (Fig. 11D), the rate of insulin release is constant at any given 
time. 
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Figure 11. (A) Raw insulin secretion data from 58 single islets and 36 pools of 10 islets. Each set 
of data points from (A) was used to model the measured cumulative insulin concentration vs time 
allowing to identify (B) fast, (C) slow, and (D) constant-rate secretors. Each exemplified set of 
data points and curve is obtained from one glucose concentration. From those curves, time 
constants as well as as 𝐾𝑝 and 𝐾′𝑝 (fast and slow secretors) and rates of insulin secretion (constant-
rate secretors) were derived. 
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5.2.5 Glucose-stimulated insulin secretion (GSIS) 
 
A GSIS assay was performed from populations of 10 islets with an aim to verify the 
functionality of the islets and to compare GSIS with an insulin secretion profile over a 72h period. 
GSIS measurements were done with 10±2 islet equivalents (IEQ) in duplicate and three different 
experiments were performed separately. The assay solution was a Krebs buffer composed of 
25mM HEPES, 115mM NaCl, 24mM NaHCO3, 5mM KCl, 1mM MgCl2 and 0.1 % (w/v) bovine 
serum albumin. Islets were first pre-incubated 1h, at 37°C and 5% CO2, in Krebs buffer 
supplemented with 2.8mM glucose. Then, islets were sequentially incubated for 1h at 37°C and 
5% CO2 in 1) 2.8mM glucose, 2) 20mM glucose, 3) 20mM glucose + 50µM 3-isobutyl-1-
methylxanthine (IBMX, I5879, Sigma-Aldrich) and 4) 2.8mM glucose, all made in Krebs buffer. 
Media were collected after every incubation and insulin was measured with the Mouse High Range 
Insulin ELISA mentioned above. 
 
5.2.6 Islets purity and viability assessment 
 
Purity and viability of the handpicked islets were performed separately on different sets of islets 
and verified for each culture for both kinetics and GSIS experiments. Purity was investigated by 
incubating handpicked islets in 200µL PBS in which 1mL of 0.01% dithizone (43820, Sigma-
Aldrich) was added to stain the islets. After 5min, samples were observed under the stereo 
microscope (Leica stereomicroscope MZFLIII at 8x). Viability was verified at the beginning and 
at the end of each culture. Staining was done using fluorescein diacetate (FDA) (F7378, Sigma-
Aldrich) and propidium iodide (PI) (P4170, Sigma-Aldrich) to visualize live (green) and dead (red) 
cells, respectively. Staining was performed by adding 20µL of a 1:10 diluted PI stock solution (0.5 
mg mL-1) and 20µL of a 1:100 diluted FDA stock solution (5 mg mL-1) to 200µL of RPMI medium 
containing the islets. After 30s, 2mL of PBS were added and the whole suspension was observed 
under a fluorescence microscope (10X) and images were taken for analysis (Nikon Eclipse 
TE2000). The percentages of cell viability within the islets were obtained by counting the number 
of pixels in an image of particular intensity and color with a Python program developed in house, 
which uses functions from the Python Image Library (PIL). The Python program is available as 
Supplemental Materials. 
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5.3 Results 
 
5.3.1 Islet characterization 
 
The in vitro release of insulin from single endocrine mouse islets and populations of 10 
islets was monitored over 72h following stimulation using four glucose concentrations i.e., 2.8mM, 
5.6mM, 11.2mM and 20mM. 
The mouse islets isolated by handpicking showed more than 95% viability, both post-
isolation at Day 0 and at 72h (Fig. 12A). After isolation, the handpicked islets were almost exempt 
of exocrine tissues (Fig. 12B). In addition to the viability and purity, the GSIS results confirmed 
the functionality of the islets (Fig. 12C). 
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Figure 12. (A) Viability of islets measured by staining with fluorescein diacetate (FDA - green) 
and propidium iodide (PI - red). Islets viability at time zero: 97.9 % ± 4.3% and at 72 hours: 95.8 
% ± 7.8%. Scale bars =100 μm. (B) Pool of ten islets stained with dithizone illustrating the 
presence of insulin-positive cells. Scale bars =100 μm. (C) Glucose-Stimulated Insulin Secretion 
(GSIS) from pools of 10 islets. 
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5.3.2 Kinetic analysis revealed distinct insulin secretion profiles: fast, slow and 
constant-rate secretors 
 
 Examples of typical insulin secretion profiles over time are illustrated in Figure 11. The 
three profiles are encountered in both single islets and pooled islets. At 2.8mM glucose, few single 
islets secreted insulin in the detectable range making the fitting of insulin secretion over time not 
possible for a majority (Figs. 13A and 14A). 
 
Figure 13. Measured cumulative insulin concentration over 72h from single islets maintained in 
(A) 2.8mM glucose, (B) 5.6mM glucose, (C) 11.2mM glucose, and (D) 20mM glucose. 
For single islets, at 5.6mM, 11.2mM, and 20mM glucose, a majority of islets were slow 
secretors (Fig. 14). This is also valid for pools of 10 islets, but only for 11.2 and 20mM glucose 
(Fig. 14). When comparing the overall percentage distribution independently of the glucose 
concentration, a majority of islets were also slow secretors (Figs. 14C and 14D). 
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Figure 14. Percentage of islets fitted for insulin secretion kinetics for the four tested glucose 
concentrations: A) single islets and B) pools of 10 islets. Overall percentage of islets fitted for 
insulin secretion kinetics: C) single islets and D) pools of 10 islets. For A and B, 100 percent 
corresponds to the total number of islets for a given glucose concentration. For C and D, 100 
percent corresponds to the total number of islets for either single islets or pools of 10-islet 
experiments. 58 single islets and 36 pools of 10 islets were used in total. 
 
5.3.3 Effect of islet size on insulin secretion 
 
No correlation between insulin secretion and islet size could be established, but few 
observations can be made. When comparing the medians and averages in Figure 13, it can be 
depicted that means and medians are close enough to each other for single islets at all glucose 
concentrations, illustrating that the data points are evenly distributed. Statistically this can be 
explained as there is less variation in insulin release among a majority of islets for the same 
concentration of glucose. 
At 2.8mM glucose, some insulin secretion was observed with bigger islets (Fig. 13A), 
although insulin secretion from those single islets resulted in very low level of cumulative insulin 
concentration. The trend of insulin secretion from single islets remains the same when the 
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cumulative insulin concentrations secreted from single islets were normalized by Islet equivalent 
(IEQ) as well as by surface area and volume of islets (Supplemental Fig. 12; Appendix A). 
At 5.6mM glucose, islets of smaller sizes secreted lower level of insulin compared to larger 
ones, but when insulin secretion was normalized per islet volume and per islet area, this trend was 
reversed or masked (Supplemental Figs. 13C and 13D; Appendix A). 
At 11.2mM glucose, more insulin is secreted from larger islets (Fig. 15A). When 
cumulative insulin concentration was normalized by islet volume, this trend was masked (Fig 15B 
and Supplemental Fig. 14; Appendix A). At 20mM glucose, when insulin secretion was 
normalized per islet volume and per islet area, smaller islets secreted more insulin (Supplemental 
Fig. 15; Appendix A). No effect of islet size could be revealed on time constants and rates of 
insulin secretion (Supplemental Figs. 16-17; Appendix A). 
 
Figure 15. Histograms presenting a comparison of the measured cumulative insulin concentration 
over 72h for single islets maintained in 11.2mM glucose in function of time (A) and (B) normalized 
by islet volume. Three-dimensional histograms were made by combining data points, as those 
exemplified in Figure 11, from different single islets for a given glucose concentration. 
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5.3.4 Effect of glucose concentration on insulin secretion 
 
Comparing averages of the cumulative insulin concentration at 72h presented in Figures 
13 and 16 reveals that statistically (t-Test: Two-Sample Assuming Unequal Variances, p < 0.05), 
when the glucose concentrations are different, the average insulin secretion values are different; 
except between 5.6 and 11.2mM and between 11.2 and 20mM for single islets as well as between 
11.2 and 20mM for groups of islets. Therefore, an augmentation in glucose concentration did not 
always correspond to an increase in the total insulin concentration at plateau. 
From Supplemental Figures 18 and 19; Appendix A, there is no effect of glucose 
concentration on time constants. Time constants vary from a few hours up to nearly 100 hours. 
However, for all glucose concentrations tested, for a majority of single islets and groups of islets, 
time constants were below 30h. When visually inspecting Supplemental Figures 18 and 19; 
Appendix A, we can conclude that time constants for slow secretors, τ1 and τ2, are of similar 
timescale for most systems, indicating that two mechanisms of almost analogous dynamics are 
governing insulin secretion. When comparing time constants, τp, of fast secretors with those of 
slow secretors, they are also of similar timescale. Time constants and rates of insulin secretion give 
an indication on how fast a process is occurring. A time constant is the time for a system response 
to reach 63.2% of its final (asymptotic, at plateau) value. No effect of glucose concentration on 
the steady-state process gains could be observed (Supplemental Figs. 20 and 21; Appendix A). At 
high-glucose concentrations, insulin secretion from single islets is representative of islet 
populations, while under low-glucose conditions distinct behaviors were observed. 
At 2.8mM glucose, for populations of 10 islets, although at low level, insulin secretion was 
detected in 8 of the 9 pools (Fig. 16A). At 5.6mM glucose for populations of 10 islets, fewer 
populations secreted insulin (Fig. 16B), and only two populations could be fitted for insulin 
secretion. At 5.6mM glucose, for pools of islets, curve fitting was often not possible due to the low 
level of insulin secretion. At 2.8 and 5.6mM, pooled islets did not behave in the same manner as 
single ones, but this was not the case at 11.2 and 20mM glucose. 
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Figure 16. Measured cumulative insulin concentration over 72h from pools of 10 islets maintained 
in (A) 2.8mM glucose, (B) 5.6mM glucose, (C) 11.2mM glucose, and (D) 20mM glucose. 
 
At 11.2mM glucose, the average value of insulin secretion was 132 ng mL-1 for single islets 
(Fig. 13C) and 1443 ng mL-1 for groups of 10 islets (Fig. 16C), which is approximately 10 fold 
higher. The same trend can be observed at 20mM i.e., the average value of insulin secretion was 
175 ng mL-1 for single islets (Fig. 13D) and 1945 ng mL-1 for pools of 10 islets (Fig. 16D). 
 
5.4 Discussion and Conclusion 
 
An important finding in this study is that insulin secretion can be monitored and modeled 
over 72h from single pancreatic islets. Seventy-two (72) hours was chosen to avoid islet loss during 
the culture.[255] Also, we know that islets can be maintained in a healthy and functional state over 
72h. The few studies reporting insulin release measurements from single islets were conducted 
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over short periods of time of up to 90 min, aiming to address a different hypothesis than ours.[256, 
257] The microfluidic systems used previously to measure insulin secretion from single islets were 
early versions and would require further improvement in terms of reliability for future use.[258] 
Those microfluidic systems represent an interesting approach to further study insulin secretion in 
response to gradients of glucose concentration in perfused conditions. In static conditions, it is 
possible that insulin levels influence insulin secretion. Also, islets are usually cultured in vitro 
before being transplanted and can be exposed to high glucose concentrations over prolonged 
periods of time so, investigating the insulin secretion kinetics over time is therefore of importance. 
Single islets and groups of islets secreted detectable insulin almost in all glucose 
concentrations, except for single islets at 2.8mM, and populations of islets at 5.6mM glucose. At 
2.8mM glucose, for a majority of single islets, either no insulin was detected in the media or no 
significant detectable insulin was found i.e., the concentration of insulin was below the lower 
insulin concentration used to build the ELISA calibration curve. This was expected as the Km for 
glucokinase, the rate-limiting step of glucose metabolism, is approximately 5mM.[259] For single 
islets at 5.6mM glucose, the percentage of islets secreting insulin was higher than that for pools of 
10 islets. Paracrine, islet-islet and cell-cell mediated signals could influence groups of islets to 
secrete less insulin at 5.6mM glucose. In a previous study, human islets secreted low level of 
insulin when exposed to 5.6mM glucose, but when those islets were dissociated into single cells 
and further used to make small aggregates, they showed improved response.[260] Thus, paracrine-
mediated signaling could be an explanation for the low level of insulin secretion observed at 
5.6mM glucose for populations of islets. In another study, however, there was no insulin secretion 
when rat pancreata were perfused for 4h with solution of 1.3-2.5mM glucose.[261] In our study, 
insulin was detected only from the largest islets when exposed to 2.8mM glucose. 
For 11.2mM and 20mM glucose, measuring insulin secretion from single islets is 
representative of populations of islets. At low-glucose concentrations i.e., 2.8 and 5.6mM glucose, 
working with single islets can allow identifying possible variation in islet response towards 
glucose. At glucose concentrations below 6mM, it is believed that several β-cells within an islet 
are non-responding, therefore, working with pools of islets at low glucose concentration could 
possibly mask this variation in insulin secretion.[262] 
 A majority of islets (ca. 50%) can be categorized as slow secretors for the four glucose 
concentrations. The functional connectivity of β-cells is high at high-glucose concentration, as 
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well as increasing glucose concentration results in an increasing number of responding β-cells to 
glucose within islets and therefore in an augmentation in insulin secretion with time.[262, 263] 
Hence, there is an initial slower response of the islets to recruit all β-cells to secrete insulin, and 
this would be explained by a slow, two-consecutive-step, model. In this study, at 20mM glucose, 
there was a partial decrease in the number of slow secretors with a corresponding increase in 
constant-rate secretors, and this was notable in pooled populations. This can be explained as, at 
20mM glucose, >80% of β-cells are involved in insulin secretion when compared to other lower 
glucose concentrations.[264] 
 Studies presenting mathematical models revealed a pattern of increased insulin secretion 
with an augmentation in glucose concentration.[262, 264, 265] A study comparing in vitro and in 
vivo insulin release over 90 min in mice revealed that, both in vitro and in vivo, the second phase 
of insulin secretion showed an ascending pattern at 16.7mM.[247] Those findings correlate, in 
part, with our results showing that when glucose concentration increased, there was an 
augmentation in insulin secretion, but this was not always valid in our case. The lack of full 
correlation between glucose concentration and insulin secretion can be explained by two 
investigations. For instance, prolonged exposure (7 days) of human islets to 11mM and 28mM 
glucose revealed a decrease in insulin accumulation in the media when compared to 5.6mM.[266] 
Also, 72h exposure of murine islets to 15mM glucose resulted in impaired function of β-cells.[267] 
Another possible mechanism that could potentially explain the observation of slow 
secretors is that caused by mass transport limitations. Mass transport of glucose into islets and of 
insulin that is released out of an islet is mainly caused by diffusion i.e., mass transport due to 
gradients of concentration. This would be represented by the slower secretion observed in slow 
secretors. In fast secretors, only one of the two mass transport steps would be in cause, explaining 
their faster dynamics. In constant-rate secretors, such diffusion barrier(s) would not be a step 
limiting insulin secretion. The different sub-populations of islets can perhaps be explained by the 
isolation procedures that can yield populations of islets with different physical states i.e., more or 
less damaged islets with different intercellular structures. Glucose-stimulated insulin secretion is 
expected to occur through a different mechanism in vitro compared to that in vivo where islets are 
vascularized. Such vasculature has been disrupted in isolated islets and passive diffusion become 
the main driving force for the glucose to reach the cells within the islets. 
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Nevertheless, our findings, extrapolated in vivo, would reveal that if the slow-secretors 
outnumber the fast-/constant-rate secretors, increased glucose levels in vivo would remain elevated 
for prolonged times, which we speculate may constitute a pre-diabetic condition.[268, 269] 
When the islet size is converted to volume, the tendency is that smaller islets are more 
potent at higher glucose concentrations (11.2mM and 20mM). Smaller islets isolated from rat 
secreted more insulin per volume when compared to the larger ones incubated with 3 and 20mM 
glucose; small islets contain more cells per volume than big ones, possibly explaining why smaller 
islets would contain more insulin per volume or per surface area [270]. 
In summary, single islets show less variation in insulin release while working at high-
glucose concentration and the values could be compared with pools of islets. For a majority of 
islets, the kinetics of insulin secretion can be modeled by a slow, two-consecutive-step, 
mechanism. Although no firm conclusion can be drawn about the effect of islet sizes, at 11.2 and 
20mM glucose it can be seen that normalizing insulin secretion over their volumes reveals that 
smaller islets secrete similar level or more insulin than bigger ones. Our method and model also 
open the possibility to investigate effects of paracrine signaling action as well as islet sizes. 
Results from traditional “static” GSIS assays do not reveal the full potential of insulin 
secretion from islets. Insulin secretion measurements done in a traditional GSIS represent the 
bottom of the cumulative insulin concentration vs time profile, well within the “slow release” 
period before insulin secretion increases in a large percentage of the islets. The same analysis 
prevails when interpreting the RRP mechanism of insulin secretion, at least with isolated islets. Is 
the RRP mechanism observed at short-term responsible for the behavior of the slow-secretors over 
longer periods of time (in our case 72h), remains a question to be investigated. 
The method and model presented here could be a future prospect for drug discovery, as the 
use of single endocrine pancreatic islets opens the door for high-throughput pre-screening of drugs 
on primary tissue. This method could limit costs, save time, reduce the number of animals, and be 
adaptable to robotic pre-screening platforms for drug development, owing to the possibility to 
perform experiments on single islets. The assay is not without limitations. Handpicking islets is 
time consuming and there is a risk to lose islets during sampling, but those pitfalls could be 
addressed. 
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Chapter 6 
 
CONCLUSION 
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Conclusions – Français 
Les travaux de cette thèse ont pour objectif la compréhension des mécanismes de survie et de 
fonctionnalité des îlots de Langerhans in vitro, pour améliorer les méthodes de transplantation 
d’îlots comme thérapie au diabète de type I. Cette thèse présente des données originales sur la 
cinétique de sécrétion de l’insuline et sur les effets de la matrice pancréatique dans la 
reconstruction de l’environnement natif des îlots. 
Le premier travail expérimental, présenté dans le chapitre 3 « La matrice extracellulaire de 
pancréas décellularisé comme support natif aux îlots », propose une solution technique à la perte 
des greffons dans la transplantation d’ilots. Comme présenté précédemment, l’encapsulation des 
îlots les protège de la réponse immunitaire de l’hôte après transplantation. Les résultats de cette 
étude montrent que cette technique de décellularisation de pancréas de souris permet d’éliminer 
efficacement tous les composants cellulaires et de conserver la matrice extracellulaire (MEC) 
native du pancréas. L’injection des îlots par une seringue via le canal pancréatique pourrait être 
une nouvelle méthode d’implantation des îlots au sein de leur MEC native. L’utilisation d’une 
MEC native pour l’encapsulation des îlots pourrait être une avancée par rapport aux techniques 
actuelles qui utilisent l’alginate ou la fibrine, notamment pour éviter les effets néfastes sur la 
fonction des îlots de la poly-lysine utilisée pour stabiliser les gels d’alginate ou des grandes 
concentrations de fibrinogène et de thrombine utilisées pour former les gels de fibrine [8, 9]. Ainsi, 
la nécessité de disposer d’un matériau d’encapsulation adéquat, c’est-à-dire proche de 
l’environnement natif des îlots et faiblement immunogène, pourrait être réalisée par des supports 
faits à partir de pancréas décellularisés. Dans cette étude, nous avons observé que les îlots incubés 
dans des supports de MEC pancréatique décellularisée étaient viables et fonctionnels après 48h, et 
que ce support n’est pas cytotoxique après 120 jours de culture de cellules INS-1 exprimant la 
GFP. La littérature montre que plusieurs organes décellularisés ont été utilisés comme support 
natif de cellules, et une étude sur les supports pancréatiques a montré des résultats encourageants 
de recellularisation de pancréas décellularisé [9]. De plus, encapsuler des îlots dans des protéines 
de la MEC a montré une amélioration de la fonctionnalité des îlots [10]. Ainsi, nous pouvons 
conclure que les pancréas décellularisés peuvent être testés comme supports biocompatibles, non 
cytotoxiques et libres de tout contenu cellulaire, dans la transplantation d’îlots. Cependant, des 
expériences complémentaires doivent être réalisées pour valider ce support comme pancréas bio-
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artificiel, notamment en faisant une évaluation in vivo de sa fonctionnalité, de la survie du greffon 
et de la réponse immunitaire liée à la greffe. 
Le travail expérimental présenté au chapitre 4, « Solubilisation de pancréas décellularisé et 
immobilisation sur des surfaces anti-adhésives pour la culture d’îlots de Langerhans », a été fait 
pour éliminer les résultats faux positifs et faux négatifs quand les îlots sont dépourvus de leur MEC 
native, cet aspect n’étant pas considéré quand les îlots sont cultivés en 2D sur des surfaces de 
cultures en polystyrène (TCPS). Trois méthodes ont été utilisées pour extraire les protéines des 
pancréas décellularisés, et chacune des méthodes a été validée par la technique de Bradford. 
L’immobilisation des protéines de MEC sur les surfaces biomimétiques a été confirmée par 
spectrométrie photo-électronique par rayons X (XPS). Les îlots isolés cultivés pendant 5 jours sur 
ces surfaces se sont montrés viables et fonctionnels, avec une production d’insuline supérieure aux 
îlots cultivés sur des surfaces contrôles (carboxymethyl dextran) et sur TCPS. Une différence de 
morphologie des îlots a également été observée sur les surfaces biomimétiques comparées au 
TCPS. Ces travaux pourraient être poursuivis en identifiant les types cellulaires qui sont 
spécifiquement maintenus sur ces surfaces. Ces expérimentations ont été limitées par la faible 
quantité d’échantillons disponibles pour les réaliser. 
Le dernier travail expérimental présenté dans ce manuscrit au chapitre 5, « La cinétique de 
sécrétion de l’insuline par des îlots individuels met en évidence différentes sous populations 
d’îlots », a eu pour but de déterminer les profils cinétiques de sécrétion de l’insuline suivant la 
concentration en glucose. Les profils cinétiques de sécrétion ont été évalués suivant le nombre 
d’îlots, seuls ou en groupe, et suivant leur taille. Un des résultats majeur de cette étude est d’avoir 
mesuré la quantité d’insuline secrétée in vitro par des îlots individuels à 8 points temporels 
différents sur une période de 72 heures. Nous avons observé trois profils cinétiques de sécrétion 
de l’insuline différents : sécrétion lente, sécrétion rapide, et sécrétion à taux constant. La majorité 
des îlots suivaient un profil de sécrétion lent (mécanisme à deux étapes consécutives). En 
normalisant la quantité d’insuline sécrétée à la taille des îlots, nous observons que les plus petits 
îlots secrètent plus d’insuline que les plus gros, même si nous ne pouvons proposer de modèle 
spécifique à cette observation. Cette étude montre également que le test traditionnel du « GSIS », 
qui est une méthode « statique », ne permet pas de mettre en évidence toute la dynamique de la 
sécrétion de l’insuline par les îlots. En effet, la méthode GSIS ne mesure qu’une portion cumulative 
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et terminale de la sécrétion d’insuline en fonction du temps, ce qui oblitère une partie du 
comportement sécrétoire des îlots. De ce fait, les indices de stimulation obtenus à partir de la 
méthode GSIS devront à l’avenir être considérés avec plus de prudence pour conclure sur les 
activités de sécrétion des îlots. La méthode de travail avec des îlots de Langerhans individuels 
pourrait ouvrir des perspectives pour du criblage à haut débit dans la pré-évaluation de 
médicaments, en particulier pour surmonter la rareté et le coût du tissu pancréatique. Cette méthode 
étant adaptable aux plateformes robotisées utilisées dans le développement de nouveaux candidats-
médicaments, elle pourrait également diminuer le nombre d’animaux, les coûts et le temps 
nécessaires aux expérimentations, en offrant la possibilité de travailler avec des îlots individuels. 
Cependant, une des limites importante de cette méthode est l’isolement manuel des îlots qui peut 
être longue et délicate. De plus, des îlots peuvent être perdus pendant l’étape d’isolement ce qui 
diminue son rendement. Ces limitations pourront être étudiées par de futurs travaux. 
En résumé, ce travail de thèse a mis en évidence l’intérêt de la MEC native du pancréas dans 
l’étude du comportement in vitro des îlots et son potentiel comme support de culture, et une 
description de la cinétique de sécrétion de l’insuline par les îlots. Ces résultats ouvrent des 
perspectives dans le développement d’un pancréas bio-artificiel transplantable. 
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Conclusions – English 
 
All the experiments in this thesis are aimed at improving the understanding of islets survival and 
functionality in vitro, for transplantation as a therapy for type I diabetes mellitus, by knowing the 
kinetics of insulin release and by applying its own pancreatic environment to rebuild islets native 
niches. 
The first experimental work described in chapter 3 titled “Decellularized pancreas as a native 
extracellular matrix scaffold for islets” attempted to address the issue of losing grafts after islet 
transplantation. As discussed earlier, islets encapsulation shields the tissue from the host immune 
system after transplantation. The results from this study convey that the techniques used for 
decellularization of the mouse pancreas could effectively remove the cellular components and 
retain the native ECM. Also, the infused mouse islets through the ductal port of a decellularized 
pancreas using a syringe would be a new way to embed islets within their native ECM. The use of 
native ECM for islets embedding would have an edge over the current techniques using alginate 
and fibrin gels for encapsulation and overcome the adverse effects on graft functions of using 
polylysine to stabilise alginate gels and using high concentrations of fibrinogen and thrombin 
causing negative impact on pancreatic islets [188, 189]. Therefore, the need of a suitable material 
for encapsulation, which is close to the native environment and has less host immune responses, 
could be met by using decellularized pancreatic scaffolds. In addition, in this study, it was observed 
that the infused islets in the decelluarized scaffolds are viable and functional after 48h in vitro and 
that the scaffold is free of cytotoxicity by culturing GFP-INS-1 cells for more than 120 days. 
Previously, it has been reported that scaffolds of many organs were successfully recellularized and 
a study on pancreatic scaffolds shows promising results in fabrication and recellularization of 
decellularized pancreas [189]. Further, encapsulating islets with ECM proteins has shown 
enhanced islets function [198]. Therefore, it can be concluded that decellularized pancreata can 
serve as biocompatible scaffolds with no cytotoxicity, and free of cellular components, to carry 
pancreatic islets for transplantation. However, it should be noted that further investigations must 
be made on this bio-artificial pancreas to study their responses following transplantation, including 
host immune rejections, functionality, and graft survival. 
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The experimental work of Chapter 4 titled, “Solubilisation of decellularized pancreata and 
immobilization on low-fouling surfaces for islet culture” was designed to eliminate any false 
positive or false negative results when the islets are devoid of their native ECM, typically not 
considered when islets are cultured on tissue culture polystyrene (TCPS) in 2D environment. Three 
methods were used to extract proteins from the decelluarized pancreata and all three methods 
extracted proteins, which was confirmed by a Bradford assay. The successful immobilization of 
proteins on the surfaces was confirmed by X-ray photoelectron spectroscopy (XPS) for the 
biomimetic surfaces. The isolated islets were cultured on these surfaces and found to be functional 
and viable at day 5 and the amount of insulin production was higher on all biomimetic surfaces 
when compared to TCPS and carboxymethyl-dextran (CMD) surfaces. In addition, the cell 
morphology was different on biomimetic surfaces compared to TCPS. It is suggested that future 
studies should involve identifying the different cell types supported by these immobilised 
biomimetics. It should also be noted that the main limitation in this experiment was dealing with 
a small sample size to perform certain studies in detail. 
The final experimental work of this thesis described in Chapter 5 titled, " Insulin secretion kinetics 
from single islets reveals distinct sub-populations", aimed to address the kinetics of insulin release 
against different glucose concentrations. Differences between kinetics of insulin secretion from 
single islets and groups of islets as well as the effect of islet size towards insulin secretion were 
investigated. One of the major findings of this study is the detection of insulin secretion from single 
isolated islets at 8 different time points for 72h in vitro. It was found that the islets secrete insulin 
according to three different kinetic models: slow secretors, fast secretors and constant-rate 
secretors, out of which most of the islets were modeled by slow secretors (two-consecutive-step 
mechanism). Although no firm conclusions can be drawn on the effects of islet size towards insulin 
secretion, it was noted that, when the islet size was normalized to their volume, the small islets 
tend to secrete more insulin. The study also highlighted that the traditional “static” GSIS assay on 
isolated islets does not reveal the full potential of insulin secretion from islets. In fact, it represents 
only the bottom of the cumulative insulin secretion concentration vs time profile, revealing very 
less information on insulin released by the islets. Therefore, care should be taken in future studies 
when concluding stimulation indices from GSIS assays and determining the insulin release 
measurements on islets. The method of working with single endocrine pancreatic islets could open 
the door for high-throughput pre-screening of drugs, to overcome the usage and availability of 
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pancreatic tissues which involves high cost. This method could also limit the number of animals, 
cost and time, while be adaptable to robotic pre-screening platforms for drug development, owing 
to the possibility of performing experiments on single islets. However, some of the limitations 
associated with these techniques are islet handpicking which could be a time consuming and 
tedious process. Also, islets could be lost during sampling. These pitfalls need to be addressed in 
the future. 
In summary, this thesis has verified that the use of native pancreatic ECM to study islet behaviour 
in vitro along with the insulin kinetics, in the hope of carrying islets in a natural bio-scaffold and 
implanting into a host, aims to offer a better solution in the field of tissue engineering and 
regenerative medicine towards the development of bio-artificial pancreas for transplantation 
treatments. Understanding and studying potential immune reactions and physiological changes in 
the host, post transplantation of these bio-scaffolds could provide a major insight in the 
development of these artificial organs. On the other hand, the emerging field of utilizing both 
decellularized scaffolds and stem cells to develop a bio-engineered organ would be a potential area 
to investigate the utility of these decellularized pancreas in the treatment of diabetes or pancreatitis 
conditions. Detailed characterization of the extracted ECM proteins and immobilization on the 
surfaces could be a natural source of in vitro test models for isolated islets to mimic the in vivo 
conditions and help in understanding islet biology and in developing drug discovery platforms for 
diabetes.  
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Appendix A 
 
 
 
 
 
 
Supplemental Figure 1. Optical microscope images of infused islets inside a decellularized 
pancreas. 
 
 
 
 
 
 
Supplemental Figure 2. Metabolic activity by 3-(4,5-dimethylthiazol-2-Yl)-2,5-
diphenyltetrazolium bromide (MTT) staining of (A) INS-1 cells following 6 days of culture in 
decellularized pancreas and (B) islets following 48 hours of culture in decellularized pancreas. 
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Supplemental Figure 3. Decellularized pancreata before and after solubilisation using the three 
methods. 
 
 
 
 
Supplemental Figure 4.  High-resolution X-ray photoelectron spectroscopy (XPS) C 1s spectra 
of the different surfaces. Pepsin control refers to activated CMD surfaces incubated in a solution 
with only pepsin without decellularized pancreata. 
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Supplemental Figure 5. Islet morphology from Day 0 to Day 3 for islets cultured on CMD 
layers and tissue culture polystyrene (TCPS). 
 
 
Supplemental Figure 6. Islet morphology from Day 0 to Day 3 for islets cultured on pepsin 
control surfaces and biomimetics bearing acetic acid extracts. 
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Supplemental Figure 7. Islet morphology from Day 0 to Day 3 for islets cultured on 
biomimetics bearing NaOH and pepsin extracts. 
 
 
 
 
Supplemental Figure 8. Glucose-stimulated insulin secretion (GSIS) of islets cultured 5 days on 
TCPS, CMD layers, biomimetics bearing pepsin extracts and biomimetics bearing NaOH 
extracts.  
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Supplemental Figure 9. Glucose-stimulated insulin secretion (GSIS) of islets cultured 5 days on 
biomimetics bearing acetic acid extracts and pepsin control surfaces.  
 
 
 
 
Supplemental Figure 10. Stimulation indices calculated from the glucose-stimulated insulin 
secretion (GSIS) assay of islets cultured 5 days on the different surfaces. 
These stimulation indices are calculated by taking ratios of insulin concentration at high glucose 
to that at the first low glucose.   
124 
 
 
 
Supporting Figure 11. Ratios of insulin concentration measured at last low glucose to that at 
first low glucose from glucose-stimulated insulin secretion (GSIS) assays of islets cultured 5 
days on the different surfaces. 
 
 
 
 
Supplemental Figure 12. (A) Measured cumulative insulin concentration, (B) normalized per 
IEQ, (C) normalized per islet volume, and (D) normalized per islet external surface area from 
single islets exposed to 2.8mM glucose for 72h. 
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Supplemental Figure 13. (A) Measured cumulative insulin concentration, (B) normalized per 
IEQ, (C) normalized per islet volume, and (D) normalized per islet external surface area from 
single islets exposed to 5.6mM glucose for 72h. 
  
Supplemental Figure 14. (A) Measured cumulative insulin concentration, (B) normalized per 
IEQ, (C) normalized per islet volume, and (D) normalized per islet external surface area from 
single islets exposed to 11.2mM glucose for 72h.  
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Supplemental Figure 15. (A) Measured cumulative insulin concentration, (B) normalized per 
IEQ, (C) normalized per islet volume, and (D) normalized per islet external surface area from 
single islets exposed to 20mM glucose for 72h. 
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Supplemental Figure 16. Time constants for single islets modeled from (A) fast secretors in 
2.8mM glucose and (B) slow secretors in 5.6mM glucose. (C) Rates of insulin secretion for 
constant-rate secretors (single islets) in 5.6mM glucose. (D) Time constants of insulin secretion 
for single islets modeled from slow secretors in 11.2mM glucose. 
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Supplemental Figure 17. Rates of insulin secretion for single islets modeled from constant-rate 
secretors in (A) 11.2mM glucose and (B) 20mM glucose. Time constants for single islets 
modeled from (C) slow secretors and (D) fast secretors in 20mM glucose.  
 
Supplemental Figure 18. From single islet experiments, time constants of fast and slow 
secretors or rates of insulin secretion of constant-rate secretors (i.e., linear systems) maintained 
72h in (A) 2.8mM glucose, (B) 5.6mM glucose, (C) 11.2mM glucose and (D) 20mM glucose. 
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Supplemental Figure 19. From pools of 10-islet experiments, time constants of fast and slow 
secretors or rates of insulin secretion of constant-rate secretors (i.e., linear systems) maintained 
72h in (A) 2.8mM glucose, (B) 5.6mM glucose, (C) 11.2mM glucose and (D) 20mM glucose.  
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Supplemental Figure 20. From single islet experiments, the steady-state process gains, 𝐾_𝑝 and 
〖𝐾′〗_𝑝, of fast and slow secretors maintained 72h in (A) 2.8mM glucose, (B) 5.6mM glucose, 
(C) 11.2mM glucose and (D) 20mM glucose. 𝐾_𝑝 and 〖𝐾′〗_𝑝  can be interpreted as the ratios 
of the predicted (modeled) cumulative insulin concentration at plateau to the glucose 
concentration used to incubate the islets.  
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Supplemental Figure 21. From pools of 10-islet experiments, the steady-state process gains, 
𝐾_𝑝 and 〖𝐾′〗_𝑝, of fast and slow secretors maintained 72h in (A) 2.8mM glucose, (B) 5.6mM 
glucose, (C) 11.2mM glucose and (D) 20mM glucose. 𝐾_𝑝 and 〖𝐾′〗_𝑝  can be interpreted as 
the ratios of the predicted (modeled) cumulative insulin concentration at plateau to the glucose 
concentration used to incubate the islets.   
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Appendix B 
 
Development of first-order function 
In this study, fast-secretor islets appear to follow the dynamics of a first-order system. A first-
order system is represented by the equation: 
 
𝜏𝑝
𝑑𝑦
𝑑𝑡
+ 𝑦 = 𝐾𝑝𝑓(𝑡) (E1) 
y is the response of the system (output) submitted to a forcing function f (input). 𝜏 p is the time 
constant indicative of the response speed. Smaller value 𝜏p will produce faster response. Kp is the 
static gain representing the ultimate variation of the output (y) to a variation of the input (f). 
For a step change of amplitude A in the input i.e., f(t) = A, equation (E1) becomes: 
 
𝜏𝑝
𝑑𝑦
𝑑𝑡
+ 𝑦 = 𝐾𝑝𝐴 (E2) 
Solution of this equation gives: 
 𝑦 = 𝐾𝑝𝐴 (1 − 𝑒
−𝑡/𝜏𝑝) (E3) 
In this study, A represents different concentrations of glucose at t=0 and y, the resulting 
measured concentration of insulin. Parameters 𝜏p and Kp can be determined by fitting 
experimental data. 
 
To explain the significance of parameters 𝜏p and Kp, an analogy could be represented by the 
following irreversible reaction where component A is transformed into component B: 
  𝐴 →  𝐵  (E4) 
In a batch reactor, since there is no flowrate in or out of the reactor, the material balance on 
component j is: 
 Rate of accumulation of component j = Rate of creation of component j by reaction (E5) 
Thus: 
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𝑑
𝑑𝑡
∫ 𝐶𝑗 𝑑𝑉 = ∫ 𝑟𝑗 𝑑𝑉  (E6) 
Cj and rj are, respectively, the concentration and reaction rate for component j, and V is the 
reactor volume. For a well-stirred reactor and assuming constant volume: 
 ∫ 𝐶𝑗 𝑑𝑉 = 𝐶𝑗V     and    ∫ 𝑟𝑗 𝑑𝑉 =  𝑟𝑗𝑉  (E7) 
For a first-order rate reaction, the reaction rate is: 
 𝑟 = 𝑘𝐶𝐴  (E8) 
k is the specific reaction rate in (time unit)-1 and CA is the concentration of component A. Since B 
will be produced at the same rate as A is consumed, we can then write: 
 𝑟𝐵 = −𝑟𝐴 = 𝑘𝐶𝐴  (E9) 
The negative sign indicates that A is disappearing. Inserting equations (E7) and (E8) in (E6), 
leads to, for component A: 
 
𝑑𝐶𝐴
𝑑𝑡
=  −𝑘𝐶𝐴  (E10) 
Considering an initial concentration CA0 at t=0, solving the equation gives: 
 𝐶𝐴 = 𝐶𝐴0𝑒
−𝑘𝑡  (E11) 
For component B: 
 
𝑑𝐶𝐵
𝑑𝑡
=  𝑟𝐵 = 𝑘𝐶𝐴 =  𝑘𝐶𝐴0𝑒
−𝑘𝑡 (E12) 
Solving: 
 
 
𝐶𝐵 = 𝐶𝐵0 +  𝐶𝐴0(1 − 𝑒
−𝑘𝑡) (E13) 
Hence, for this system with 𝐶𝐵0 = 0, a step change CA0 at t=0 gives: 
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𝜏𝑝 =
1
𝑘
 
(E14) 
 
𝐾𝑝 =
𝐶𝐵∞
𝐶𝐴0
 
(E15) 
Where 𝐶𝐵∞ is the concentration on component B when 𝑡 →  ∞. If the reaction is complete i.e., all 
reactive are consumed, 𝐶𝐵∞ = 𝐶𝐴0 and 𝐾𝑝 = 1. An example of first-order response for both 
species is presented in Figure S1 for 𝐶𝐴0 = 1  and 𝑘 = 1. 
 
Figure S1 
Development of second-order function 
Contrary to fast secretors which start to produce insulin rapidly at the beginning of a kinetic 
experiment, slow-secretor islets initial response is sluggish. The sigmoidal response obtained are 
typical of a second-order system. This type of response can be the results of two different 
processes that operate in series. For example, a component which requires a significant time to 
diffuse through a porous solid phase before a reaction can occur could display a second-order 
response. As an analogy, we can demonstrate the dynamic of two irreversible reactions in series. 
In the first reaction, component A decomposes to form the intermediate B. In the second 
reaction, B forms the final product C: 
 𝐴 →  𝐵 →  𝐶  (E16) 
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If for both reactions, the reaction rates are of first-order: 
 𝑟1  =  𝑘1𝐶𝐴    ,    𝑟2  =  𝑘2𝐶𝐵  (E17) 
The material balances on the components give: 
 𝑑𝐶𝐴
𝑑𝑡
=  −𝑟1 =  −𝑘1𝐶𝐴 (E18) 
 𝑑𝐶𝐵
𝑑𝑡
=  𝑟1 − 𝑟2 =  𝑘1𝐶𝐴 − 𝑘2𝐶𝐵 
(E19) 
 𝑑𝐶𝐶
𝑑𝑡
=  𝑟2 =  𝑘2𝐶𝐵 
(E20) 
For component A, the material balance can be solved like before: 
 𝐶𝐴 = 𝐶𝐴0𝑒
−𝑘1𝑡  (E21) 
For component B, inserting (E21) in (E19): 
 𝑑𝐶𝐵
𝑑𝑡
 +  𝑘2𝐶𝐵 =    𝑘1𝐶𝐴0𝑒
−𝑘1𝑡 
(E22) 
The solution of this equation is: 
 
𝐶𝐵 =  𝐶𝐵0 𝑒
−𝑘2𝑡 + 𝐶𝐴0 
𝑘1
𝑘1 − 𝑘2
 (𝑒−𝑘1𝑡 −  𝑒−𝑘2𝑡) 
(E23) 
If 𝐶𝐵0 = 0, (E23) is reduced to: 
 
𝐶𝐵 =  𝐶𝐴0 
𝑘1
𝑘1 − 𝑘2
 (𝑒−𝑘1𝑡 −  𝑒−𝑘2𝑡) 
(E24) 
For component C, inserting (E24) in (E20): 
 𝑑𝐶𝐶
𝑑𝑡
=  𝐶𝐴0 
𝑘1𝑘2
𝑘1 − 𝑘2
 (𝑒−𝑘1𝑡 −  𝑒−𝑘2𝑡) 
(E25) 
 
 
Assuming 𝐶𝐶0 = 0, the solution of (E25) is: 
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𝐶𝐶 =  𝐶𝐴0 [1 −
1
𝑘2 − 𝑘1
 (𝑘2𝑒
−𝑘1𝑡 −  𝑘1𝑒
−𝑘2𝑡)] 
(E26) 
Since 𝜏𝑝1 = 1/𝑘1 and 𝜏𝑝2 = 1/𝑘2, equation (E26) is equivalent to equation 2. 
Figure S2 presents the second-order response of two reactions in series with conditions 𝐶𝐴0 = 1 ,  
𝑘1 = 1  and 𝑘2 = 3 . 
 
Figure S2 
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Appendix C 
 
Python program used to determine percentage of live and dead cells 
 
import os 
from PIL import Image 
import matplotlib as mpl 
mpl.use("Agg") 
import matplotlib.pyplot as plt 
class image(): 
 def __init__(self): 
  # image name 
  self.name = "NAN" 
  # image file name 
  self.file = "NAN" 
  # image dimensions: height and width 
  self.size = [] 
  # file type of the image 
  self.type = "NAN" 
  # number of pixels of with colors R, G and B 
  self.RGB = {'R':-1, 'G':-1, 'B':-1} 
  # image histogram data -- Tonal variations in R, G and B 
  self.HData = {'R':[], 'G':[], 'B':[]} 
##############################################################################
####### 
def Load(imageFName): 
 # Load an image by filename 
 if os.path.isfile(imageFName): 
  img = Image.open(imageFName) 
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  # Create an image object and set its name 
  imageObject = image() 
  imageObject.file = imageFName 
  imageObject.name = imageFName[imageFName.index("."):] 
  imageObject.type = imageObject.name = imageFName[:imageFName.index(".")] 
  imageObject.size = img.size 
  return imageObject 
 else: 
  print("\033[91m File %s does not exist \033[0m" % imageFName) 
##############################################################################
####### 
def IsImageFile(name): 
 # determine if a file/folder is an image file 
 if os.path.exists(name): 
  return 0 
 else: 
  imageExtensions = [".pdf", ".png", ".jpg", ".jpeg", ".tiff"] 
  for extn in imageExtensions: 
   if extn in name[-len(extn):]: 
    return 1; 
  return 0; 
##############################################################################
####### 
def LoadDir(dirName): 
 
 
 
 
